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ABSTRACT 
 
Adenosine receptors (ARs) are seven trans-membrane domain G-protein coupled 
receptors named A1, A2A, A2B and A3. Adenosine, the main agonist, acting on these 
receptors exerts a broad spectrum of physiological and pathological functions. 
Adenosine production increases dramatically when there is a discrepancy between the 
rates of ATP synthesis and ATP utilization, for example when work load is markedly 
enhances or when the supply of oxygen and glucose is limiting as in ischemia. 
Adenosine receptors are expressed in all body tissues with different concentrations and 
functions. One of the most important role is explain in the regulation of inflammatory 
function, a field where A2AAR is an important player. 
Parkinson’s disease (PD) is a pathology with a complex etiology, involving both genetic 
and environmental factors. The cardinal signs of PD relate to motor dysfunction, 
psychiatric and dysautonomic symptoms. PD is characterized by prominent loss of 
dopaminergic neurons in the substantia nigra pars compacta in relatively early stages of 
the disease, depletion of striatal dopamine, and the presence of intraneuronal inclusions 
called Lewy bodies. Current knowledge highlight the important role of inflammation in 
Parkinson’s disease. The central nervous system was supposed to be an immune 
privileged site, in which immune cells of the periphery could not enter or rarely entered. 
Today we know that peripheral immune responses can trigger inflammation and 
exacerbation of central nervous system degeneration in several neurodegenerative 
diseases. When cytokines, such as tumor necrosis factor (TNF)-α, are secreted by 
activated glia in the brain or are present in circulating blood, permeability of the blood 
brain barrier is increased. 
The primary aim of this study was to investigate the expression, affinity and density of 
adenosine receptors in lymphocytes and neutrophils of PD patients compared to healthy 
subjects. This study revealed a specific A2AAR alteration correlating with disease 
severity: patients with higher A2AAR density and lower affinity were more likely to 
exhibit motor complications. An increase in A2AAR density in putamen patients was 
found, an alteration that mirrors a similar up-regulation in human peripheral blood cells. 
Moreover, how expected, we measured high levels of adenosine and TNF-α in plasma of 
PD patients. Interesting we found out a statistically significant linear correlation among 
the A2AAR density and TNF-α levels. Elevated levels of TNF-α in PD brains amplify 
and sustain the neuroinflammation leading to dopaminergic neurons destruction. 
Moreover, several studies highlight a close relation between TNF-α release and A2AAR. 
To shed some light on the functional adenosine-dopamine interaction, we examined the 
effects of well-known A2AAR agonists and antagonists on dopamine uptake in the rat 
adrenal pheochromocytoma cell line after differentiation into a neuronal phenotype by 
nerve growth factor. Our results show that A2AAR antagonists decreased dopamine 
uptake, and an opposite effect was mediated by A2AAR agonists.  
In conclusion our data prove the double importance of A2AAR in Parkinson’s disease: a 
biomarker useful for diagnose and a potential therapeutic target for PD. 
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LIST OF ABBREVIATION 
 
- ADP: adenosine di-phosphate 
- AMP: adenosine mono-phosphate 
- ATP: adenosine tri-phosphate 
- CCPA: 2-Chloro-N6-cyclopentyladenosine 
- CGS 21680: 4-[2-[[6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin 2-
yl]amino]ethyl]benzenepropanoic acid hydrochloride 
- CHO: chinese hamster ovary 
- Cl-IB MECA: 2-Chloro-N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide 
- CNS: central nervous system 
- COX: cyclooxygenase 
- CPA: N6-cyclopentyladenosine 
- CREB: cAMP response element-binding protein 
- DA: dopamine 
- ENTPD: ectonucleoside triphosphate diphosphohydrolase 
- HIF: hypoxia inducible factor 
- IB-MECA: 1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-
D-ribofuranuronamide 
- IL: interleukine 
- KO: knock out 
- LB: Lewy body 
- LPS: lypopolisaccaride 
- MAO: monoamino oxidase 
- MPTP: 1-metil 4-fenil 1,2,3,6-tetraidro-piridina 
- NECA: 5'-N-ethylcarboxamido adenosine 
- NF-kB: nuclear factor kB 
- NK cells: natural killer 
- NOS: nitrous oxide systems 
- PBS: phosphate buffered saline 
- PC12: pheochromocytoma cell 
- PD81723: 2-Amino-4,5-dimethyl-3-thienyl)-[3-(trifluoromethyl) phenyl] methanone 
- PGE: prostaglandin  
- PKA: protein kinase A 
- PLC: phospolipase C 
- R-PIA: N6-(R-phenylisoprophyl) adenosine 
- SCH 58261: 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo [1,5-
c]pyrimidin-5-amine 
- Tgf: tumor growth factor 
- TNF: tumor necrosis factor 
- VEGF: vascular endothelium growth factor 
- WT: wild type 
- ZM 241385: 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol 
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INDRODUCTION 
1. Adenosine signaling: the beginning 
Purines appear to be the most ancient chemical cellular messenger in animals and 
plants. The purinergic signaling system employs extracellular purines and pyrimidines 
as signaling molecules both released from living cells. These transmitters act upon 
target cells through activation of two classes of receptors, the metabotropic P1 receptors 
to adenosine, and nucleotide receptors of the P2 family, which is subdivided into P2Y 
metabotropic and P2X ionotropic sub-classes [1].   
Adenosine is present ubiquitously and its receptors are widely distributed through the 
body exerting a broad spectrum of physiological and pathophysiological functions [2]. 
Data from techniques of molecular biology suggest that P2X ion channel receptors 
appeared early in evolution while G-protein coupled P1 and P2Y receptors were 
introduced at the same time or later [1]. 
The first evidence of adenosine effect date back to eighty years ago. In the University of 
Cambridge, A.N. Drury and A. Szent-Györgyi, begin their study of a unknown 
substance extract from bullock’s heart muscle. They chose the heart like study model 
because “the heart, therefore, is an admirable test object for any substance which may 
be suppose to influence cell activity”. The injection of this substance into a dog or 
guinea pig caused bradycardia. After exclusion of vagus nerve involvement and 
influence of inorganic component used in the protein extraction, they wrote “we are 
strongly of the opinion, as a result of these observations, than our substance is identical 
with adenylic acid, and we shall refer in this paper to the substance isolated by us as 
adenylic acid”. Adenosine prepared from yeast nucleic acid has an identical action to 
adenylic acid. The lower arterial pressure was due in part to the cardiac slowing and in 
part to a general arterial dilatation [3].  
 
 
 
 
 
 
Fig.1 Influence of injection of 40 mg adenosine into femoral vein [3]. 
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Two years later Bennet and Drury confirmed the previous experiment on the heart and 
came in light the effect of adenosine on others guinea pig body tissues: uterus 
constriction, local accumulation of leucocytes, considerable fall of temperature after 
subcutaneous injection [4].  
 
 
 
 
Fig. 2 Influence of subcutaneous injection of adenosine upon rectal temperature of the guinea-
pig. a) Injection of saline, b) and c) injection of 50 mg and 100 mg of adenosine [4]. 
 
 
Severity of trauma, magnitude of the loss of tissue adenine nucleotides and the release 
of breakdown products correlated with protective effects and vasodilatation, 
anticoagulatory effect, energy transfer suppose to be due to adenosine nucleotides enter 
cells. Bennet and Drury studied that a lack of energy owing to hypoxia caused the 
breakdown of myocardial adenine nucleotides able to cause coronary vasodilatation: 
increasing oxygen supply to an energy-depleted tissue, subsequently limiting its own 
formation like a classical tenet of homeostasis and negative feedback [5].  
From other study on heart it was understood that methylxanthines acted as adenosine 
antagonists [6]. From 1960 synthesize of more stable analogues started yielding the 
adenosine analogue 2-chloroadenosine, R-PIA and NECA [7]. The different effects of 
these compounds away the idea of a therapeutic benefit but helping to define the 
subtypes of adenosine receptors (a concept become clear in 1970s).  
For many years it was though that the only source of extracellular ATP acting on 
purinoceptors was damaged or dying cells. It is now recognized that ATP release from 
healty cells is a physiological mechanism in response to shear stress, stretch or osmotic 
swelling, hypoxia or stimulation by various agents [8]. 
The concept of purinergic signaling system was first proposed by Geoffrey Burnstock in 
1970, when proposed ATP like a neurotransmitter [9]. In 1978 Burnstock made the 
important suggestion that there exist a family of receptors called purinergic receptors 
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that can be subgrouped into two subclasses, P1 and P2 [10]. This classification was 
based on the selective potency of ATP, ADP, AMP and adenosine, the effectiveness of 
methylxanthines as antagonists and mediation or not by adenylate cyclase [11]. This 
hypothesis met considerable resistance because ATP had been established as 
intracellular energy source and it was thought that such a ubiquitous molecule was 
unlikely to be involved in selective extracellular signaling [8]. The Purinergic 
Hypothesis included the presence of purinoceptors and a few years later Burnstock 
proposed a basis for distinguish P1 (adenosine) from P2 (ATP/ADP) receptors and in 
1985 distinguished two type of P2 purinoceptor, P2X and P2Y [12]. In 1990s with 
studies of transduction mechanism and cloning of P2X and P2Y it was proposed that 
there were two families of P2 receptors, P2X ionotropic ligand-gated ion channel 
receptors and P2Y metabotropic G-protein-coupled receptors. 
A classification into A1 and A2 adenosine receptor was proposed in 1979 [13] along 
with the A2A and A2B nomenclature for the two cloned receptors showing considerable 
sequence homology and similar signal transduction mechanism, distinguished by 
pharmacological criteria [14]. 
 
 
2.  Adenosine signaling: current knowledge 
 
ADENOSINE 
Adenosine is the main agonist at the P1 receptor class and in addition the adenosine 
metabolite inosine can activate at least some of the receptors [15]. The concentration of 
adenosine in the extracellular compartment is the consequence of many biological 
processes, including extracellular adenosine production from intracellular sources, 
transport, and metabolism to inosine or AMP. ATP can be release from vescicles with a 
“kiss and run” mechanism (vescicles open and close transiently), from the lysosome by 
exocytosis or by an uncontrolled leakage from necrotic cells and inflammatory or 
vascular endothelial cell release. 
Adenosine can increase dramatically from the basal level, estimate to be in the range of 
30-200 nM. Very minor changes in steady state ATP levels in the cell will translate into 
major changes in the intracellular adenosine concentrations (100,000 times higher). The 
adenosine production from hydrolysis of adenosine nucleotides, from ATP or ADP 
breakdown is controlled through a two-step enzymatic reaction: conversion of ATP or 
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ADP to AMP by ENTPD1 or CD39 followed by AMP hydrolysis to adenosine by ecto-
5’-nucleotidase (NT5E or CD53) [16]. Adenosine generated intracellulary is transported 
into the extracellular space mainly via specific bi-directional transporters through 
facilitated diffusion. In some tissues there are nucleoside transporter protein capable of 
maintaining high adenosine concentration gradient: ENT1 and ENT2, CTN1 and CTN2 
[17,18]. 
Adenosine is formed intracellulary whenever there is a discrepancy between the rates of 
ATP synthesis and ATP utilization, for example when work load is markedly enhanced 
or when the supply of oxygen and glucose is limiting as in ischemia. In ischemic areas 
of after a massive tissue trauma leading to cell death by necrosis can increase to perhaps 
30 μM [19]. 
 
 
Fig.3 Adenosine synthesis, metabolism and transport in physiological condition [7]. 
  
The malfunction of adenosine metabolism is the cause of some serious pathologies. In 
human, absence of adenosine deaminase induces immunodeficiency (SCID-ADA). 
Patients with this pathology show skeletal [20], lung, liver [21] and neural abnormalities 
[22]. The absence of ADA induces increase of deoxyadenosine converted in 
deoxyadenosinetriphosphatase (dATP) by adenosine kinase. dATP causes 
lymphocytoxicity in thymus through induction of apoptosis in developing thymocytes 
[23]. 
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ADENOSINE RECEPTORS 
Forty years ago was postulated the existence of adenosine receptors, an hypothesis 
based on the competitive antagonist of adenosine activity by methylxanthines. Twenty 
years later four receptors were cloned from several mammalian species and identified as 
members of G protein-coupled family. These receptors show an high sequence 
homology among different species [24]. 
 
 
 
 
 
 
 
 
 
Fig.4 Tree graph showing adenosine receptors gene homology among different species [24]. 
 
A1 adenosine receptor 
A1 adenosine receptor (A1AR) is the most conserved receptor subtype among species. 
The gene, ADORA1, have chromosomal localization 1q32.1. It is expressed throughout 
the body with the highest levels found in the brain (cortex, hippocampus and 
cerebellum) especially at excitatory nerve endings, but also in heart, kidney, testis and 
adipose tissue. The A1AR has been shown to couple with Gi-1, Gi-2, Gi-3 and G0 but not 
with Gs or Gz proteins. Responses to A1ARs activation are blocked by pertussis toxin 
which is compatible with an involvement of the Gi/G0 family of G-proteins [14]. The 
activation of A1R induces inhibition of adenylate cyclase, activates potassium channels, 
block transiently calcium and IP3 levels by activating PLC. A model for this receptor 
was proposed after studies based on sequence analysis and computer-assisted molecular 
modeling [25]. 
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Fig.5 Model of A1AR protein based on sequence analysis and computer-assisted molecular 
modeling [14]. 
 
Chemical modification of histidine residues in the receptors transmembrane domain, 
one in helix VI and one in helix VII, strongly affects ligand binding. Glutamate residues 
in the second extracellular loop as being important for ligand recognition. From 
extensive mutagenesis analysis, consisting of single aminoacid replacement in human, 
canine and bovine species, other aminoacids are resulted very important in ligand 
recognition [24].  
Biological functions of A1AR were studied in mice lacking of ADORA1 gene. This 
animals showed a reduction of fertility, lifespan [26] and an increase of seizures risk 
[27]. A1AR in afferent arterioles mediate vasoconstriction and inhibition of renin 
secretion and tubular A1AR appear to modify tubular NaCl absorption [28]. In brain 
A1AR are down-regulated by hypoxia in glioma cells and up-regulates in human 
temporal lobe in epilepsy. A deeply hypothermic and hypometabolic state was 
pharmacologically induced in a nonhibernating rat by A1AR agonist CHA [29]. In 
murine astrocytes A1AR indirectly reduce the LPS-mediated HIF-1α accumulation, a 
master regulator of oxygen homeostasis [30]. It is known that astrocytes regulate the 
reduction of depressive symptoms after sleep deprivation, an effect that seems to be 
mediate by A1AR: pharmacological activation of this receptor mimicked the effect of 
sleep deprivation on depression phenotypes [31]. It has been already demonstrated that 
IL-6 can increase the survival of retinal ganglion cells in culture and this trophic effect 
is mediated by adenosine receptor A1AR activation [32]. 
Activation of A1AR in the central and peripheral nervous systems produces an 
antinociceptive effect. The local application of CCPA in a pain model induced by a 
B 
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tibial nerve injury inhibited thermal hyperalgesia, but was less effective against 
mechanical allodynia [33]. The analgesic effect during inflammation could be ascribes 
at the activation of opioid receptors [34].  
Activation of the A1AR in adipocytes causes inhibition of lipolysis also in pathological 
conditions like insulin resistance, diabetes and dyslipidemia [35].   
From a study that compare WT and A1AR KO mice results that after administration of 
an adenosine analogue, insulin induced lipogenesis in A1AR (+/+), but not in A1R (-/-) 
adipocytes. Body weight was similar in young A1AR (+/+) and A1AR (-/-) mice, but old 
male A1AR (-/-) mice were heavier than wild type controls. Plasma levels of free fatty 
acids, glycerol and triglycerides were significantly lower in A1AR (+/+) than in A1AR (-
/-) [36]. After 8-16 h of CPA injection increase of 2-to 10-fold serum level of leptin, the 
appetite hormone [37]. 
 
A2A adenosine receptor 
A2A adenosine receptor (A2AAR) gene is localized on 22q11.23 chromosome, have 
multiple exons, which encode alternative transcripts, whose expression is driven by at 
least four independent promoters. The regulation of these promoters is highly 
responsive to alterations in the extracellular environment and particular sensitive to 
changes in the concentrations of exogenous and endogenous factors involved in 
inflammation [38]. This is a receptor coupled to Gs protein, and if over-expressed can 
interact with other G-proteins like Golf in striatum [39]. 
 
 
 
 
 
 
 
 
 
 
 
Fig.6 Crystal structure of A2AAR bound to the antagonist ZM 241385 [40]. 
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Stimulation of A2AAR activates PKA that phosphorylates CREB on Ser 133. CREB 
activation competed with NFkB-p65 for CBP mediating the anti-inflammatory effect 
[41]. A2AAR have independent G-protein action by C-terminus tail (120 aminoacids 
highly conserved among species) interaction with other proteins. One of this protein is 
F-actin, cross linking protein that mediates the internalization of A2AARs after 
stimulation contributing to receptor desensitization [42].  
High levels of A2AAR are found in the striatum, immune cells of the spleen, thymus, 
leukocytes and blood plates, but also, any less, in heart, lung and blood vessels [7], 
where is involved in many physiological and pathological process. A2AAR in the brain 
interacts with several neurotransmitters to regulate motor activity, psychiatric behaviors, 
sleep-wake cycle and neuronal cell death. In peripheral tissue A2AAR have a crucial role 
in the modulation of inflammation, myocardial oxygen consumption, coronary blood 
flow, angiogenesis and control of cancer pathogenesis [7]. In immune system adenosine 
binding A2AAR controls lymphocyte trafficking in response to tissue injury or infection 
mediating extravasations of lymphocytes through blood vessels.  
It was demonstrated that activation of A2AAR significantly suppresses the deposition of 
collagen types I and III, reduces the infiltration of CD4+ T lymphocytes, and attenuates 
the expression of TGF-β1 and ROCK1, in a mouse model of renal interstitial fibrosis, a 
pathological process of chronic kidney diseases leading to renal function deterioration 
[43].  
Adenosine regulates the function of the innate and adaptive immune systems mainly 
through A2AAR activation on monocytes/macrophages, dendritic cells, mast cells, 
neutrophils, endothelial cells, eosinophils, epithelial cells, as well as lymphocytes, NK 
cells, and NKT cells [38]. 
In the heart A2AAR engagement protects against ischemia-reperfusion injury following 
an acute ischemic episode and inducing profound oxidative/nitrosative stress, capillary 
pluging, edema and reduction in coronary vascular flow [44]. In the lung inosine acting 
on A2AARs can regulate ovalbumin induced allergic inflammation modulating 
inflammatory processes and cytokines release [45].  
In lung, deficiency of A2AAR increases activation of proinflammatory transcription 
factor Nf-KB and augmented expression of inducible NO synthase [46]. Moreover 
adenosine by this receptor reduces bowel inflammation [47]. 
In the liver A2AAR is expressed on Kuppfer cells, hepatocytes and hepatic stellate cells. 
Engaging of A2AAR induces a reduction of inflammatory cytokines in a model of liver 
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injury [48] and ischemia reperfusion injury [49]. In the kidney A2AAR is expressed in 
microvasculature [50] and his activation reduces injury following ischemia-reperfusion 
in rats [51].  
Methotrexate, a therapeutic drug for rheumatoid arthritis, has immunosuppressive and 
anti-inflammatory effects mediated by increasing of adenosine levels, effect less 
effective in A2AAR KO mice [52]. In the joint A2AAR exert his anti-inflammatory 
action in leukocytes, chondrocytes [53] and synovial cells [38]. A2AARs regulate also 
the intrinsic circadian clock in immune cells playing an important role in circadian 
rhythms in rheumatoid arthritis [54]. It was investigated A2AAR density and 
functionality in RA progression by using a longitudinal study in patients afflicted by 
rheumatoid arthritis before and after methotrexate, anti-TNFα agents or rituximab 
treatments: in lymphocytes obtained from RA patients, the A2AAR up-regulation was 
gradually reduced in function of the treatment time. Moreover in adjuvant-induced 
arthritis model in rats it was showed the efficacy of the A2AAR agonist, CGS 21680, in 
comparison with standard therapies [55].  
Within brain, A2AAR expression levels are highly concentrated in dorsal and ventral 
striatum (on striatopallidal) as well as in olfactory tubercle. It is also recognized that 
A2AARs are expressed at substantially lower levels outside striatum in brain regions 
including hippocampus and cortex [56].  
A2AAR is involved in sleep induction and it was demonstrate that caffeine induces 
wakefulness in A1AR but not in A2AAR KO mice, demonstrating that this effect is 
mediated by antagonism on A2AAR [57,58]. A genetic variant of the A2AAR gene in 
humans is associated with individual sensitivity to effect of caffeine on sleep [59]. 
KO mice for A2AAR show a reduced explorative activity, higher anxiety, slow response 
to acute pain stimuli and male are much more aggressive than WT mice [60].  
A2AAR inactivation in the brain has been associated with protection against brain 
damage after ischemia, excitotoxicity, traumatic injury and neurodegeneration in 
Parkinson and Alzheimer disease. Adult mice exposed to A2AAR antagonists including 
caffeine during pregnancy and lactation displayed loss of hippocampal GABA neurons 
and some cognitive deficits demonstrating the important role of A2AAR on the neural 
development [61].  
Interestingly, while pharmacological blockade of A2AAR by antagonists induces motor 
stimulation, adult gb-A2AAR KO mice consistently exhibit reduced spontaneous activity 
compared to their WT [62], a discrepancy that may relate to partial blockade and/or 
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acute/short-term blockade of A2AARs by selective antagonists compared to complete 
absence and/or long-term depletion of the receptor in these knockout models [63]. 
The involvement of A2AARs in neurodegenerative disease, where the inflammatory 
component is considerable, was deeply investigated by our research group. Data from a 
study on Huntington’s disease patients indicate the existence of an aberrant A2AAR 
phenotype in the peripheral blood cells of subjects carrying the HD mutation [64] and 
the alteration of A2AAR in lymphocytes reflects the presence of the mutant protein [65]. 
In R6/2 HD transgenic mouse model, it was seen a transient increase in A2AAR density 
and A2AAR cAMP production at early presymptomatic ages and a decreasing A2AAR 
mRNA, a discrepancy that suggests a compensatory mechanism [66]. A positive 
correlation was found between A2AAR density in lymphocytes of patients afflicted of 
neurodegenerative diseases and gravity and progression of the pathology, like as 
Amyotrophic and Lateral Sclerosis, Multiple Sclerosis and Parkinson’s disease [67-69] 
indicating a possible protective effect of this receptor subtype.  
A2AAR play a major role in coronary vasodilatatory properties of adenosine, and it is 
expressed in coronary endothelial cells as well as in coronary smooth muscle cells. 
Along with vascular cells, A2AAR is expressed in additional cell types in the 
myocardium [70]. Many studies show that optimal A2AAR agonist-mediated protection 
occurs with low doses infused for at least 1 hour. Higher concentrations are associated 
with significant hypotension and reflex tachycardia and could also induce coronary steal 
[71,72].  
 
A2B adenosine receptor 
 
A2B adenosine receptor (A2BAR) is codificated by ADORA2B gene with chromosomic 
localization 17p12-p11.2 and contains a single intron that interrupt the coding region 
[73]. 
A2BARs are expressed on various cells of hematopoietic origin: neutrophils [74], 
lymphocytes [75] and even platelets [76]. 
A2BAR is rarely achieved under physiological conditions because requires micromolar 
adenosine concentrations. Nevertheless Adora2B-KO mice have very strong 
phenotypes, show low-grade inflammation [77] and vascular leakiness in several organs 
[78]. During conditions in which adenosine levels are elevated, such as hypoxia, 
ischaemia or inflammation, A2BAR is involved in tissue adaptation to hypoxia, 
increased ischemic tolerance or attenuation of acute inflammation [7]. Further studies 
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identified a strong dependence of A2BAR by HIF-1α: binding of HIF to a hypoxia 
responsive element on the promoter resulting in increased of A2BAR mRNA and protein 
[79].  
Inflammatory mediators associated with inflammation have been demonstrated to 
increase A2BAR gene transcription, like bacterial lipopolysaccharide, TNF-α and IL-1β 
[80]. Other inflammatory mediator including PGE2, IL-6 and IL-4 are not associated 
with an increase in transcription but rather with stabilization of A2BAR mRNA during 
inflammation. 
A2BAR couples to Gs to activate adenyl cyclase and increase intracellular cAMP levels 
[81] and can couple to the Gq family of G-proteins to activate PLC and increase 
intracellular calcium [82]. It appears the G protein coupling of the receptor is cell type 
dependent and coupling to Gs results in an anti-inflammatory response while coupling 
to Gq could potentially results in a pro-inflammatory response [80]. 
Activation of the A2BAR has been shown to promote bone cell differentiation, control 
glucose homeostasis [83,84] and regulate hyperlipidaemia and atherosclerosis [85]. 
Stimulation of A2BAR protects against trauma-hemorrhagic shock-induced lung injury 
[86].  
A2BAR promote tumor cell growth by VEGF in Lewis lung carcinoma A2BKO mice: 
these mice exhibited significantly attenuated tumor growth and longer survival time 
compared to WT controls [87].  
Pharmacologic activation of A2BAR results in proinflammatory effects relevant to the 
progression of asthma but genetic removal of A2BARs leads to exaggerate responses in 
models of acute inflammation. A2BAR gene ablation in ovalbumin-induced chronic 
pulmonary inflammation attenuates allergen-induced chronic pulmonary inflammation 
[88].  
In a mouse model of COPD it was demonstrated that the blockade of ADORA2B is able 
to attenuate the development of a pulmonary hypertension phenotype that correlates 
with reduced levels of hyaluronan deposition in the vessels and down regulation of 
genes involved in the synthesis of hyaluronan [89].  
Conversely, A2BARs were proposed to play an inhibitory role in degranulation of mouse 
bone marrow derived mast cells (BMMCs), based on the finding that A2BKO mice show 
an exaggerated antigen-induced mast cell degranulation [90]. Studies in HMC-1 cells 
showed that only A2BAR, but not A2AARs or A3ARs stimulate secretion of angiogenic 
factors IL-8 and VEGF, and the Th2 cytokines IL-13 and IL-4 [91-94].  
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A2BARs expression has been detected in vascular endothelium and smooth muscle cells 
where it has been implicated in the regulation of vascular tone through receptor-
mediated vaso-dilatory effects counteracting A1AR-mediated vasoconstriction [95].  
Due to their large surface area, mucosal organs are particularly prone to hypoxia and 
ischemia associated inflammation then adenosine via the A2BARs dampens mucosal 
inflammation and tissue injury during intestinal ischemia or colitis [96], and A2BAR KO 
mice show a reduction in induced colonic inflammation compared with their wild-type 
counterparts [97].  
 
A3 adenosine receptor 
The human A3 adenosine receptor (A3AR) was cloned in 1993 from a striatal cDNA 
library. There is a considerable variation in the pharmacology and distribution, and 
hence function, of A3ARs among species. The protein, of 318 amino acids, exhibits 
almost 30% difference at the amino acid level between human and rat [7]. 
KO of the A3AR in mice was surprising, resulting in marked phenotypes even at loca-
tions where the receptors are very sparse. 
The phenotype of mice that lack the A3AR shows a marked diurnal variation in activity, 
heart rate and reduction of body temperature [98]. 
A3AR represents a good therapeutic target for tumoral pathologies because is 
overexpressed in cancer and in inflammatory cells, while low expression is found in 
normal cells. An overexpression was found in different neoplastic cells including 
leukemia, lymphoma, astrocytoma, melanoma, mesothelioma and pineal tumor cells 
[99]. 
Interesting study were made about the increase expression of A3AR in tumor tissues 
derived from patients with colon, breast, small cell lung, pancreatic and hepatocellular 
carcinomas and melanoma in comparison with adjacent normal cells [100]. In breast 
cancer tissue A3AR mRNA increase of 1.27-fold respect to normal tissues [101], and in 
patients with colorectal adenocarcinomas A3AR expression was higher in cancer tissue 
compared with normal mucosa from the same individuals, moreover the expression of 
these receptors in peripheral blood cells was approximately 3-fold higher compared 
with healthy subjects [102].   
The pharmacological stimulation of A3ARs with agonist IB-MECA resulted in a 
significant cell growth inhibition of the human cancer cell line MCF [103] and in the 
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inhibition of androgen-independent PC-3 prostate human carcinoma cells by 
deregulation of Wnt and NF-kappa B signaling pathways [104]. 
A3AR activation with the specific agonist CF101 inhibits the development of cancer 
growth in a murine model of colon carcinoma via modulation of GSK-3 β and NF-kB 
[105]. 
An A3AR over expression was described in human and experimental animal model of 
inflammatory disease. A3ARs reduce the LPS-mediated HIF-1α accumulation in murine 
astrocytes, resulting in a downregulation of genes involved in inflammation and 
hypoxic injury [30]. In a murine model of ischemia-reperfusion activation of A3AR by 
Cl-IB-MECA attenuates lung dysfunction, inflammation, and neutrophil activation and 
chemotaxis [106]. In some case disrupting neutrophils function could adversely affect 
innate immune responses conferring to A3AR a pro-inflammatory role [107]. In a mice 
model of acute pancreatitis, administration of IB-MECA attenuate the histological 
parameters of inflammation [108]. In patients with rheumatoid arthritis, lymphocytes 
show an increase of A3ARs in comparison with healthy controls and activation of these 
receptors inhibit NF-kB pathway and diminished inflammatory cytokines such as TNF-
α, IL-1β and IL-6. Moreover A3AR density inversely correlated with clinical 
parameters, DAS28 and DAS, suggesting a direct role of the endogenous activation of 
these receptors in the control of RA joint inflammation [109]. In an experimental model 
of autoimmune uveitis, CF101 inhibiting pro-inflammatoy cytokines production and 
apoptosis of inflammatory cells, improved uveitis clinical score [110]. 
A3AR could be considered a biological marker because levels of A3AR in PBMCs 
mirror the receptor expression levels in tumor or inflammatory tissue: infact, it is known 
that pro-inflammatory cytokines, especially TNF-α, binding their receptors, initiate 
downstream signaling that result in an upregulation of transcription factors, like NF-kB, 
that bind A3AR promoter region [99]. In vitro and in vivo model of hepatocellular 
carcinoma, CF102 treatment decreases the expression level of NF-kB, and TNF-α and 
prevented apoptosis in the liver with a decreased expression levels of pro-apoptotic 
proteins Bax and Bad. In addition, CF102-induced apoptosis of Hep-3B cells via de-
regulation of the PI3K-NF-κB signaling pathway, resulting in up-regulation of pro-
apoptotic proteins [111]. Normally, adenosine modulates colonic cholinergic motility 
via activation of A3ARs in the myenteric plexus. A3AR-mediated tonic inhibitory 
control by adenosine was impaired in inflamed bowel, despite increased density of 
functioning and pharmacologically recruitable A3ARs [112]. 
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3. FUTURE: AGONISTS AND/OR ANTAGONISTS OF 
ADENOSINE RECEPTORS IN CLINICAL PRACTICE 
Due to the involment of adenosine in numerous pathological processes (Fig. 7), the 
importance of its therapeutically targeting is clear. In the beginning, because the 
complexity of their signaling, adenosine agonists or antagonists cannot be delivered in a 
manner that is clinically effective and safe [7]. Actually adenosine molecule named 
Adenocard was approved by Food and Drug Administration (FDA) in 1989 for the 
treatment of paroxysmal supraventricular tachycardia restoring normal sinus rhythm in 
patients. Adenoscan was approved by FDA in 1995, indicated as an adjunct to thallium-
201 myocardial perfusion scintigraphy in patients unable to exercise adequately for its 
vasodilatory effect (FDA web site). 
In 2008 Regadenoson (Lexiscan, Astellas Pharma), an A2AAR agonist is approved by 
FDA for myocardial perfusion imaging in patients with suspected coronary disease.  
 
 
 
4.  
5.  
6.  
7.  
8.  
9.  
10. 
11. 
12. 
13. 
Fig. 7- Possible disease targets for selective adenosine receptor ligands [113].  
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4. PARKINSON DISEASE 
Parkinson’s disease (PD) is a pathology with a complex etiology, involving both genetic 
and environmental factors.  
Currently its definition is not so different from the first description made by James 
Parkinson: 
“Involuntary tremulous motion, with lessened 
muscular power, in parts not in action and even 
when supported; with a propensity to bend the 
trunk forwards, and to pass from a walking to a 
running pace: the senses and intellects  
being uninjured” (J.Parkinson, 1817). 
 
The cardinal signs of PD relate to motor dysfunction and include resting tremor, 
bradykinesia, rigidity and postural reflex impairment. Other manifestations include 
psychiatric symptoms such as anxiety and depression and dysautonomic symptoms such 
as hypotension and constipation, paresthesias, cramps, olfactory dysfunction, seborrheic 
dermatitis and increase of cognitive deficit with the disease progression.  
The main pathological characteristic associated with the motor deficits of PD is 
degeneration of the dopaminergic neurons of the pars compacta of the substantia nigra 
(SNpc) leading to loss of dopamine in the striatum. The loss of these neurons, which 
normally contains neuromelanin, produces the classic SNpc depigmentation [114]. 
Symptoms do not develop until about 50–60% of the nigral neurons are lost and 80–
85% of the dopamine content of the striatum is depleted.  
The combination of asymmetry of symptoms and signs, the presence of a resting tremor 
with the classic 4-to-6-Hz frequency, and a good response to levodopa best differentiate 
PD from parkinsonism due to other causes. 
PD is characterized by the progressive death of selected but heterogeneous populations 
of neurons, including the neuromelanin-laden dopaminergic neurons of SNpc, selected 
dopaminergic brain-stem nuclei (both catecholaminergic and serotoninergic), the 
cholinergic nucleus basalis of Meynert, hypothalamic neurons, and small cortical 
neurons (particularly in the cingulate gyrus and entorhinal cortex), as well as the 
olfactory bulb, sympathetic ganglia, and parasympathetic neurons in the gut [115].  
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The Lewy Body (LB) is an eosinophilic hyaline inclusion consistently observed in 
selectively vulnerable neuronal populations. LBs in the brain stem and basal forebrain 
are usually more than 15 μm in diameter, with a spherical, dense hyaline core, a clear 
halo. 
The LB contains a variety of other constituents, elements of LB filaments, proteins that 
represent a cellular response to LB formation, enzymes such as phosphatases and 
kinases, and other cytosolic proteins that probably become trapped in LB during their 
formation [116]. Elevation of iron levels detected in the pars compacta of the substantia 
nigra in patients with PD is believed to be an important factor in causing oxidative 
stress [117]. The metabolism of endogenous dopamine may also produce a number of 
toxic bioproducts that could contribute to the heightened state of oxidative stress in PD 
[118]. 
PD is a complex network disorder in which abnormal activity in groups of neurons in 
the basal ganglia strongly affect the excitability, oscillatory activity, synchrony and 
sensory responses of areas of the cerebral cortex that are involved in the planning and 
execution of movements.  
In the basal ganglia function the stimulation of the direct and indirect striatal pathways 
provokes motor activation and motor inhibition. In PD the equilibrium of the basal 
ganglia circuits is last due to the depletion in striatal dopamine caused by degeneration 
of SN dopaminergic neurons [119]. Direct pathway is a monosynaptic inhibitory 
pathway that is mediated by GABA, whereas the indirect pathway is a polysynaptic net 
excitatory pathway that includes the Globus pallidum (GP) and STN. Input to the 
striatal neurons comes from cortex and thalamus. Increased activity of the direct 
pathway results in increased movement via an inhibitory effect on thalamocortical 
projection neurons, whereas increased activity of the indirect pathway results in the 
opposite effect. Dopamine receptors in the motor circuit can be either excitatory (D1) or 
inhibitory (D2). The release of striatal dopamine decrease GPi and SNr activity via 
stimulation of the direct pathway (D1 receptors in the SNc) and inhibition of the indirect 
pathway (D2 receptors). Inhibition of dopamine release has the opposite effect [120]. 
DA deficiency causes overactivity of the indirect pathway, resulting in an excessive 
glutamatergic stimulation drive to the internal segment of the GP and pars reticulata of 
the SN and reduced activity of the inhibitory GABAergic direct pathway, further 
disinhibiting the activity of the internal segment of the GP and of the SNr. Because 
these structures use the inhibitory neurotransmitter GABA, the increased output of the 
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basal ganglia leads to excessive inhibition and, effectively, to a shutdown of the 
thalamic and brainstem nuclei that receive their outflow (Fig.8). The excessive thalamic 
inhibition leads to suppression of the cortical motor system, possibly resulting in 
akinesia, rigidity, and tremor, whereas the inhibitory descending projection to brain-
stem locomotor areas may contribute to abnormalities of gait and posture [115]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 - Basal ganglia neurotransmission in health and Parkinson’s Disease. Numbers (from 1 to 
9) indicate the neuro-stimulation/inhibition motor control pathway (red arrow: 
inhibition of neurotransmission; green arrow: stimulation of neurotransmission; dotted 
arrow: impairment of the neurotransmission).   
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EPIDEMIOLOGICAL INFORMATIONS 
PD is a very common disease with a decline in incidence in older age groups which may 
be the result of difficulties in assigning a PD diagnosis in patients with extensive co-
morbidities. 
Incidence rates for PD in studies that reported results for all age groups ranged between 
1.5 and 22 per 100,000 person-years; studies restricted to older populations (above 55 or 
65 years) reported overall incidence rates between 410 and 529 per 100,000 person-
years. Variations across ethnic groups occur maybe because different environmental 
exposures and different susceptibility genes in own genetic pattern. In Europe incidence 
rates is between 9 and 22 per 100,000 person-years, with a rate of 410 and 529 per 
100,000 person-years in studies based on populations above 55 or 65 years. In North 
American studies incidence rates ranged between 11 and 13 per 100,000 person-years, 
with an incidence rate of 224 per 100,000 person-years in individuals 65 years or above. 
In Asia incidence rates is between 1.5 and 17 per 100,000 person-years. 
The incidence of PD seems to be higher in men than in women whit a ratio of 1.49 and 
this suggested possible protective effect of estrogens, higher frequency of intensity of 
occupational toxin exposure and recessive susceptibility genes on the X chromosome. 
Gender difference decreased with increasing age, as men had higher mortality rates than 
women.  
Overall prevalence ranged between 31 and 970 per 100,000. In US and Europe PD 
prevalence among people 65 years or older it was estimated at 950 per 100,000. 
Another study estimated the number of individuals above age 50 with PD in the world 
at between 4.1 and 4.6 million in 2005. By year 2030 the number was projected to more 
than double to between 8.7 and 9.3 million [121]. 
 
RISK FACTORS 
As with many neurodegenerative diseases, age appears to be a clear risk factor for PD: 
both men and women have an increasing risk of PD with increasing age. 
Men have a higher incidence rate of PD than women and one interpretation is that there 
are potentially protective effects of estrogen because there is some evidence that women 
with PD were more likely to have undergone a hysterectomy or oophorectomy than 
those who did not, develop PD. Testosterone could have harmful effects on the 
development of PD, could be a recessive susceptibility gene on chromosome X, or male 
lifestyle could predispose to this pathology [122]. 
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Genetic mutations in the α-Syn gene [123] (SNCA) are rare and include point mutations 
and whole-locus multiplications. Duplications are detected in approximately 1% to 2% 
of the PD families, and these patients often display a classical PD phenotype; 
triplications and point mutations are exceedingly rare, found in a few families of Greek, 
German and Spanish origin and show more severe phenotypes [124,125]. 
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known cause 
of autosomal dominant PD. LRRK2 mutations explain approximately 10% of patients 
and the most common mutation is Gly2019Ser. This mutation is frequent in some 
populations from South Europe, but very common among Arab patients from North 
Africa and among Ashkenazi Jewish patients [126].  
The most recently described gene involved in autosomal dominant PD is VPS35 within 
affected members of a Swiss kindred with late-onset, autosomal dominant PD.  
Mutation in PRKN, PINK1, and DJ-1 genes cause autosomal-recessive forms of PD 
[127,128]. Mutations in ATP13A2 (PARK9), PLA2G6 (PARK14), and FBXO7 
(PARK15), cause more-rare forms of recessive parkinsonism, usually with very early 
onset (<30 years) and atypical clinical features [129]. 
PD is associated with rural living or farming and numerous epidemiological studies 
have suggested that pesticide or herbicides exposure is closely related to the 
development of PD, with a risk increased of 1.8-fold (pesticide 1.6-fold and to 
herbicides 1.4-fold) [130]. No association was observed with fungicides, rodenticides, 
organochlorines, and organophosphates but 2-fold increase in risk for exposure to 
paraquat [131]. 
MPTP, a meperidine analogue occasionally used accidentally by heroin addicts, is a 
potent neurotoxin with selective effects on nigral dopaminergic neurons. MPTP toxicity 
is due to the inhibition of complex I (NADH–ubiquinone oxidoreductase) of the 
mitochondrial electron-transport chain, leading to energy failure and cell death. 
 
INFLAMMATORY COMPONENT IN PD 
The central nervous system was supposed to be an “immune privileged” site, in which 
immune cells of the periphery could not enter or rarely entered, and thus the two 
systems had little to no interaction. 
Today we know that peripheral immune responses can trigger inflammation and 
exacerbation of CNS degeneration in several neurodegenerative diseases, increasing 
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neuronal vulnerability to other neurodegenerative insults, such as those caused by aging, 
oxidative stress, environmental toxins or genetic predisposition (fig.9) [132]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.9- Peripheral inflammatory reactions can also initiate neurodegenerative changes that are 
often associated with the preclinical phase of many neurodegenerative disease [132]. 
 
The cause of the neuronal loss in PD is poorly understood but neuroinflammatory 
mechanism might contribute to the cascade of events leading to neuronal degeneration. 
This mechanism comprise microglial activation, astrogliosis, and  lymphocytic 
infiltration. Inflammation in PD is not merely a consequence of neuronal degeneration 
but may be involved in its progression by producing deleterious proinflammatory 
molecules [133]. Data from post-mortem studies revealed the presence of activated 
microglia cells within the substantia nigra of PD patients [134]. The density of 
astrocytes in SNpc is lower in post mortem brain patients than in healthy individuals, 
this implies few surrounding cells witch detoxify oxygen free radicals [135]. In addition 
some peripheral cells can enter the brain parenchyma during the neurodegenerative 
process because changes in blood brain barrier function might occur in the brain of 
patients with PD, in fact was found an increase density of endothelial cells and change 
in brain capillaries in the SN of patients was found, maybe like a consequence of 
reactive species released by activate microglia [136]. In striatum of post mortem brain 
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of patients it was found an increase of TNF-α, TGF-β1, IL-1β, IL-6 and IL-2. 
Furthermore dopaminergic neurons express receptors for these cytokines suggesting that 
they are sensitive to them which in this way can exert toxic effects [133]. 
Proinflammatory cytokines can indirectly induce a toxic effect leading expression of the 
inducible form of NOS or COX- 2 [137]. In body fluids of PD patients there is an 
increase of active T-cells, CD4+ bright CD8+ dull lymphocytes usually increase after a 
viral infection, a condition that might contribute to the pathogenesis of the disease 
[138]. Other studies, supporting the inflammatory role in PD progression, show that 
men with high levels of IL-6 in blood have increased risk to develop PD. However the 
risk of this disorder was lower in people who regularly took non-steroidal anti-
inflammatory drugs [139]. 
A recent study provides evidence that enteric inflammation, occurring in PD patients, 
reinforce the role of peripheral inflammation in the initiation and/or the progression of 
the disease [140].  
LRRK2 is a gene related to Parkinson’s disease susceptibility and also to Crohn’s 
disease and numerous scientist support the hypothesis that the detrimental effects 
mediated by Parkinson’s disease LRRK2 mutations may initiate in the periphery and 
extend to the central nervous system as a consequence of increased levels of pro-
inflammatory factors permeable to the blood brain barrier [141]. 
 
MANAGEMENT OF PD 
The management of PD includes symptomatic and regenerative treatments. Because of 
the link to dopamine depletion, treatment of PD has centered on various dopamine 
replacement strategies including dopamine precursor, dopamine agonist and agents that 
inhibit the metabolism of dopamine. 
MAO-B inhibitors were developed as a means to increase synaptic dopamine levels and 
half-life. Two MAO-B inhibitors, selegilin and rasagiline, are currently licensed in 
Europe and North America for the symptomatic improvement of early Parkinson’s 
disease. A third MAO-B inhibitor (safinamide) is currently under development in phase 
III clinical trials as adjuvant therapy to either a dopamine agonist or levodopa [142].  
Levodopa/Carbidopa, respectively, Levodopa/Benserazide are the most effective 
treatment for PD. Levodopa induces complications such as dyskinesias motor 
fluctuations: “wearing-off ” and “on–off ” phenomena. 
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Motor fluctuations occur in 50 percent of patients after 5 years of levodopa therapy and 
the proportion affected increases to 70 percent among those treated for more than 15 
years. Wearing off can be defined as a perception of loss of mobility or dexterity, 
usually taking place gradually over a period of minutes (up to an hour) and usually 
having a close temporal relation to the timing of antiparkinsonian medications. On–off 
effects are unpredictable and generally sudden occurrences (lasting seconds to minutes) 
of shifts between on and off periods that are not apparently related to the timing of 
antiparkinsonian medication. These off periods last minutes to hours and do not include 
transient episodes of “freezing” (also referred to as “motor blocks”; the initiation or 
continuation of a motor act such as walking is arrested for few seconds) or stress-
induced tremor, which are both components of the underlying disease and occur even in 
the absence of treatment. Once fluctuations and dyskinesia emerge, the 
pharmacodynamic response changes, resulting in a narrowing of the “therapeutic 
window” and a specific levodopa threshold is needed for a sufficient clinical response 
[143]. 
 
Diagnoses 
McGhee and colleagues summarized the main characteristics of a good biomarker for 
PD: his change have to follow the neurodegeneration, have to show an association with 
the clinical phenotype, have a direct association with the disease progression and have 
not be influenced by symptomatic treatment, be sensitive reflecting small changes in 
disease progression, quick and cheap to measure, safe and tolerable for the patients, 
suitable for measurement across different centers. They analyzed numerous scientific 
work on serum/plasma/blood biomarkers, brain SPECT, brain PET, CSF, brain MRI, 
concluding that they found insufficient evidence to recommend the use of any 
biomarker for disease progression in PD [144]. 
Diagnoses in PD is based on medical history of patients, evaluation of signs and 
symptoms, neurological and physical examination. Imaging test includes single proton 
emission computed tomography (SPECT), sonography, positron emission tomography 
(PET), functional magnetic resonance imaging (fMRI) [145]. In 2011 the FDA 
approved a specialized imaging technique called DaTscan that allows doctors to capture 
detailed pictures of the dopamine system in brain. Unfortunately, because there is no 
definitive test for PD, and because these disease symptoms are similar to those of other 
neurological conditions, the misdiagnosis rate remains significant. PET and SPECT 
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imaging use a number of radiotracers for in vivo assessment of normal and abnormal 
brain function. Cerebral blood flow and glucose can be mapped with radiolabeled water 
or glucose. SPECT imaging is less expensive and more available than PET that has a 
superior spatial resolution and higher sensitivity. fMRI is available, don’t require the 
injection of a radiotracer [146]. 
The Unified Parkinson's Disease Rating Scale (UPDRS) is a scale that was developed as 
an effort to incorporate elements from existing scales to provide a comprehensive 
means to monitor PD, related disability and impairment. The scale has four components, 
largely derived from preexisting scales: part I-Mentation, Behaviour and Mood; part II-
Activities of daily living; Part III-Motor; Part IV-complications. UPDRS is often 
accompanied with Hoehn and Yahr scale [147]. Hoehn and Yahr scale analyzed the 
motor decline progression, deterioration in quality of life, neuroimaging studies of 
dopaminergic loss and it is focused on issues of unilateral versus bilateral disease [148]. 
The “mini mental state examination” (MMSE) is useful for the evaluation of the 
cognitive deficit and it is named “mini” because excludes questions concerning mood 
and abnormal mental experience [149]. Usually for the PD diagnosis are used also the 
Geriatric Depression Scale (GDS) and the Frontal Assessment Battery: the first test 
represent a reliable and valid self-rating depression screening scale for elderly 
populations [150] and the second is a bedside cognitive and behavioral battery to assess 
frontal lobe functions [151]. 
 
Evidences of A2AAR useful in Parkinson’s disease management 
In recent years much research was focused on identifying non dopaminegic compounds 
to be used as adjuvants to L-DOPA therapy. Among several new classes of drugs, 
A2AAR antagonists have emerged as the most promising candidates [119]. From a 30 
years study emerged that incidence of PD decline consistently with increased amount of 
coffee intake, from 10.4 per 10000 person-years in men who drank no coffee to 1.9 per 
10000 person years in men who drank at least 28 oz/day: caffeine, an adenosine 
receptors antagonist, intake is associated with a significantly lower incidence of PD 
[152].  
Patients with PD have altered adenosine A2AAR expression in the basal ganglia, 
suggesting a pathogenic role for these receptor. A2AAR mRNA levels (+129%) and 
[
3
H]-SCH58261 specific binding (+32%) were increased in the putamen of dyskinetic 
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patients compared to controls. This increase was also significant compared with 
dyskinetic PD patient (+60% and +24% for mRNA and [
3
H]-SCH58261 specific 
binding respectively). These data suggest that A2AAR increase is associated with the 
development of dyskinesias [153].  
The deletion of the A2AAR in mice protects against dopaminergic neuron degeneration 
induced by a mutant human α-synuclein transgene. The A2AAR KO completely prevents 
loss of dopamine and dopaminergic neurons suggesting that A2AARs appear required 
for neurotoxicity in a mutant α-synuclein model of PD [154]. 
The A2AAR is largely coexpressed with D2DR in the striatum where modulates 
dopaminergic activity and antagonizes D2DR mediates neurochemical effects by direct 
A2AAR-D2DR interaction. The role of this interaction was analyzed by using mice 
genetically deficient in A2AARs or D2DRs or both. In D2 KO and wild-type mice the 
A2AAR agonist reduced spontaneous and amphetamine-induced locomotion, instead in 
the same mice A2AAR antagonist produce motor stimulation [155].  
Neurochemical studies have shown that activation of A2AARs reduces the binding 
affinity of D2 agonist to their receptors [156].  
By immunofluorescence experiments was demonstrated the co-localization of A2AAR 
and D2DR in cell membranes of SH-SY5Y human neuroblastoma cell stably transfected 
with human D2DR and in cultured striatal cells (figure 10). Furthermore long term 
exposure to A2AAR and D2DR agonists in D2DR cotransfected neuroblastoma cells 
resulted in coaggregation, cointernalization and codesensitization of A2AAR and D2DR 
[157]. 
 
 
 
Fig.10- Double immunofluorescence staining in SH-SY5Y neuroblastoma cells stably 
transfected with the human D2DR. a) A2AAR immunoreactivity (green); b) D2DR 
immunoreactivity (red); c) superimposition of images revealing the colocalization of 
A2AAR and D2DR (yellow) [157]. 
 
A2AAR and D2DR have reciprocal antagonistic interactions that regulate GABAergic 
neurons. A2AAR activation in the indirect pathway opposes the action of D2DR 
activation by means of an intramembrane interaction, whereas stimulation of D2DRs 
inhibits A2AAR induced activation of adenylyl cyclase. Stimulation of A2AAR facilitates 
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GABA release whereas D2DR stimulation inhibits this process. Inhibition of A2AAR and 
D2DR produces opposite effects [120].  
The antiparkinsonian effect of A2AAR antagonist was well studied in different PD 
animal models. In 6-OHDA lesioned rats rendered dyskynetic by prior treatment with 
levodopa, A2AAR antagonist produce and additive reduction in motor disability with 
levodopa [158]. In MPTP treated common marmosets, oral administration of 
istradefylline increased locomotor activity [159]. In levodopa primed MPTP treated 
cynomologous monkeys, istradefylline significantly improved locomotor function, 
comparable to that observed with levodopa (50 mg) but with little or no dyskinesia 
[160].  
In human a potent and selective A2AAR antagonist, preladenant, was tested on 253 
patients of 15 countries. This study revealed that 5 and 10 mg of preladenant twice daily 
(fig. 11) might be clinically useful to reduce off time in patients with PD and motor 
fluctuation [161].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11- Preladenant administration: mean change in daily off and on time from baseline to week 
12. *p=0·024 versus placebo. †p=0·0489 versus placebo. ‡p=0·0486 versus placebo. 
§p=0·019 versus placebo[161]. 
CHAPTER II- AIM OF THE STUDY 
30 
            
           
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
AIM OF THE STUDY 
II 
CHAPTER II- AIM OF THE STUDY 
31 
AIM OF THE STUDY 
 
PD is a neurodegenerative disorder with a strong inflammatory component. Increasing 
evidences suggest a direct involvement of adenosine in PD and its key role in the 
regulation of neurotransmission. For example epidemiological studies suggest that 
higher coffee and caffeine (unspecific antagonist for adenosine receptors) assumption, is 
associated with a significantly lower incidence of PD [162]. A2A is the main adenosine 
receptor involved in this disorder. In the brain is localized prevalently in the striatum 
and it is co-expressed with D2 dopamine receptors: here exerts an antagonist effect on 
D2DR and if up-regulated induces motor impairment.  
The aim of this study was to investigate the presence and a possible density and 
functional alteration of A2AARs and D2DRs in post mortem putamen of PD patients 
compared to control subjects. Furthermore from analysis on blood of patients we found 
high levels of TNF-α in plasma, then we were interested to understand the involvement 
of inflammation, in particular of this cytokine, in the neuronal up-regulation of A2AAR. 
For this purpose we analyzed the effect of TNF-α on A2AAR density and cAMP 
production in PC12 cell line before and after treatment with NGF to induce a neuronal 
phenotype in these cells. Moreover we are interested to understand if the involvement of 
A2AAR in PD is also associated to a modification in dopamine reuptake. For this 
purpose we measured the dopamine quantity after stimulation and/or inhibition of 
A2AAR with specific agonist and antagonist.  
The other goal of our study is the identification of a possible correlation between 
A2AAR density in the blood and clinical parameters of PD patients to understand if 
peripheral A2AAR alteration could mirror the brain damage and then use it like a 
biomarker for PD. To this end it was evaluated the affinity and density of A1-, A2A, A2B- 
and A3ARs in lymphocyte and neutrophil membranes from PD patients and healthy 
control subjects. These data were correlated with score values of different scales 
estimating motor and cognitive impairment of PD patients. 
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METHODS 
1. Subjects 
Brains of postmortem PD patients and healthy controls were derived from Netherlands 
Brain Bank of the Department of the Netherlands Institute for Neuroscience, 
Amsterdam, Netherlands. Human brain samples from 7 PD patients (3 men and 4 
women) were obtained as well as from 7 controls (3 men and 4 women) who died with 
no neurological disorders. All autopsies were carried out within 12 hours of death, and 
the brain fragments were immediately frozen at -80°C until use in the experimental 
assays (Table 1M).  
We collected peripheral blood samples of 129 PD patients (82 men and 47 women) 
attending the Neurological Clinic of the University of Ferrara, Italy. PD diagnosis was 
based on established diagnostic criteria. All patients were followed up by the same 
neurologist. Clinical data were obtained from medical records of patients and direct 
interviews, throughout a structured questionnaire administered to patients and their 
relatives. Demographic data, family and clinical history, and age at onset of initial 
symptoms were recorded. Pharmacological data regarding antiparkinsonian drugs and 
other concurrent treatments were also registered. The levodopa equivalent daily dose 
(LEDD) was computed according to standard conversion factors. The severity of PD 
symptoms and signs was assessed using the Unified Parkinson’s Disease Rating Scale 
(UPDRS) and the Hoehn and Yahr’s staging. The mini–mental state examination 
(MMSE), the Geriatric Depression Scale (GDS), and the Frontal Assessment Battery 
(FAB) were also administered. The blood samples were obtained from PD patients on 
the same day of the clinical examination and interview. Clinical features of included PD 
subjects are summarized in Table 2M. 
123 healthy control subjects (79 men and 44 women) were volunteers from Ferrara 
University Hospital Blood Bank and were matched for similar age to the cohort of PD 
patients. The study was approved by the local Ethics Committee of the University 
Hospital of Ferrara, and informed consent was obtained from each participant in 
accordance with the principles outlined in the Declaration of Helsinki.  
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NBB autopsy code Diagnosis Sex 
Age at 
death 
(years) 
Delay to 
autopsy 
(hours:min) 
Brain 
tissue 
pH 
96-032 96/052 191 J non-demented control 
F 
60 08:25 6.60 
97-043 S97/133 100 W1 non-demented control 
M 
68 10:10 7.08 
93-110 *93/215 119 F non-demented control 
M 
73 08:45 6.11 
04-049 S04/158 351 B non-demented control 
F 
77 08:20 6.48 
04-021 S04/057 351 B non-demented control 
M 
80 06:30 6.43 
98-056 S98/123 100 W1 non-demented control 
F 
83 05:15 7.30 
96-078 S96/238 191 J non-demented control 
F 
87 08:00 6.91 
 
03-078 S03/239 300 PUT3 
PD with dementia 
F 61 04:30 6.30 
94-026 S94/069 136 K2 
PD 
M 68 06:00 6.70 
05-080 S05/298 300 PUT3 
PD 
M 73 06:35 6.28 
94-092 S94/245 104 G 
PD 
F 77 09:40 6.86 
93-007 S93/014 104 G 
PD 
M 79 05:25 6.15 
94-021 S94/062 136 K2 
PD 
F 83 05:00 6.58 
05-045 S05/160 300 PUT3 
PD with dementia 
F 87 05:25 6.44 
 
Table 1M- Characteristics of postmortem healthy controls and PD patients. 
 
Characteristics of PD patients  
Age (mean ± SD) 64.8 (8.4) 
Time since diagnosis (median interquartile range) years 5 (3-6) 
Hoehn & Yahr staping (mean ± SD) 2.33 (0.8) 
UPDRS II (mean ± SD) 9.4 (7.7) 
UPDRS III (mean ± SD) 22.8 (14.5) 
MMSE score (mean ± SD) 26.2 (3.3) 
LEDD (mean ± SD) 546.7 (352) 
 
Table 2M- Demographic and clinical characteristics of included PD patients involved in the 
blood examinations. 
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Table 3M- Percentage of PD patients involved in our study that assumed specific drugs. 
 
2. Preparation of human putamen membranes 
Human putamen of PD patients and controls was homogenized in 50 mM Tris-HCl 
buffer, pH 7.4, with a Polytron (Kinematica Inc., Bohemia, NY, USA) and centrifuged 
for 20 min at 48,000 g. To study A2AARs, the membrane pellet was suspended in 50 
mM Tris-HCl buffer, pH 7.4, containing 10 mM MgCl2 and was incubated with 2 IU/ml 
adenosine deaminase for 30 min at 37°C. Similar aliquots of membranes were 
suspended in 50 mM Tris-HCl buffer, pH 7.4, with the aim of investigating D2DRs. 
 
 
3. Preparation of blood peripheral cells or membranes 
Lymphocytes or neutrophils were isolated and prepared from the peripheral blood of PD 
patients and control subjects. The blood was supplemented with 6% (by weight) 
Dextran T500 solution (Sigma, St. Louis, MO, USA). Cells were pelletted by 
centrifugation for 5 min at 250 g, suspended in Krebs-Ringer phosphate buffer, and 
layered onto 10 ml of Fycoll-Hypaque (GE Healthcare, Little Chalfont, UK). After 
centrifugation, lymphocytes or neutrophils were diluted at 1 x 10
6
 cells/sample and used 
immediately in cAMP experiments. To obtain membrane suspensions, cell fractions 
were centrifuged in hypotonic buffer at 20,000 g for 10 min. The pellet was 
resuspended in Tris-HCl 50 mM buffer, pH 7.4, containing 2 UI/ml adenosine 
deaminase (Sigma), incubated for 30 min at 37°C, and used for radioligand binding 
assays. The proteins concentration was determined by a BCA protein assay kit (Pierce, 
Rockford, IL, USA) with bovine albumin as the reference standard. 
 
Patients drug assumption (% of patients) 
L-DOPA (monotherapy) 10 
DOPAMINE AGONIST 
(monotherapy) 
3.3 
POLYTHERAPY 43.3 
L-DOPA AND DOPAMINE 
AGONISTS 
36.6 
ANTIPSYCHOTICS 6.6 
ANTIDEPRESSANTS 33.3 
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4. PC12 cell culture 
PC12 cells were maintained in DMEM medium supplemented with 5% FCS, 10% horse 
serum, 2 mM glutamine, 100 μg/ml penicillin, and 100 μg/ml streptomycin in a 
humidified atmosphere (5% CO2) at 37°C. Cells were subcultured 3x/wk at a density of 
5x10
5
/ml. Differentiation was achieved by treatment with 50 ng/ml NGF (Sigma) for 1 
week. 
Cells were treated with TNF-α (100 ng/ml; Sigma) for 24 h and then harvested for 
radioligand binding experiments to examine A2AARs and D2DRs. PC12 cells were also 
treated with a potent A2AAR agonist, CGS 21680 (1 μM; Sigma) and with a selective 
A2AAR antagonist, SCH 58261 (1 μM; Tocris, Bristol, UK) for 24 h and then used in 
A2AAR and D2DR saturation binding experiments. 
 
5. Real-time RT-PCR experiments 
Total cytoplasmic RNA was extracted from human putamen fractions and human 
lymphocytes by the acid guanidinium thiocyanate phenol method. Quantitative real-
time RT-PCR assay of A1-, A2A-, A2B-, and A3R mRNAs was carried out using a gene 
specific fluorescently labeled TaqMan MGB probe (minor groove binder) in an ABI 
Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). 
For the real-time RT-PCR of A1-, A2A-, A2B-, and A3ARs, the Assay-on-Demand Gene 
Expression Products NM 000674, NM000675, NM 000676, and NM 000677 (Applied 
Biosystems) were used, respectively. For the real-time RT-PCR of the reference gene, 
the endogenous control human β-actin kit was used, and the probe was fluorescently 
labeled with VIC (Applied Biosystems). 
 
6. Western blotting analysis 
Human putamen fractions and human lymphocytes were washed with ice-cold 
phosphate buffered saline (PBS) containing 1 mM sodium orthovanadate, 10
4
 mM 4-(2-
aminoethyl)-benzenesulfonyl fluoride, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM 
bestatin, 1.5 mM pepstatin A, and 1.4 mM E-64. Then cells or tissues were lysed in 
Triton lysis buffer, and the protein concentration was determined using a BCA protein 
assay kit (Pierce, Rockford, IL, USA). Aliquots of total protein sample (50 μg) were 
analyzed using antibodies specific for human A2AARs (Alpha Diagnostic, San Antonio, 
TX, USA; 1 μg/ml dilution). Filters were washed and incubated for 1 h at room 
temperature with peroxidase-conjugated secondary antibodies (1: 2000 dilution). 
CHAPTER III-METHODS 
37 
Specific reactions were revealed with enhanced chemiluminescence Western blotting 
detection reagent (GE Healthcare). 
 
7. Saturation binding to D2DRs and ARs 
Binding to D2DRs in human putamen aliquots was determined by using [
3
H]-spiperone 
(specific activity 16 Ci/mmol; Perkin Elmer, Boston, MA, USA) as radioligand. The 
tissue membranes (50 μg protein/assay) were incubated for 15 min at 37°C with 8–10 
concentrations of the radioligand [
3
H]-spiperone (0.05–5 nM). Non specific binding was 
determined in the presence of 1 μM butaclamole.  
Human lymphocyte and neutrophil membranes (60 μg protein/assay) with [3H]-DPCPX 
(0.01–20 nM) as radioligand (specific activity 120 Ci/mmol; Perkin Elmer) were 
incubated for 90 min at 25°C. Nonspecific binding was determined in the presence of 
DPCPX 1 μM. Saturation binding to A2AARs in human putamen or blood-cell 
membranes (60 μg protein/assay) was determined by using [3H]-ZM 241385 (0.01–20 
nM; specific activity 27 Ci/mmol; Biotrend, Cologne, Germany) as radioligand and 
were incubated for 60 min at 4°C. Nonspecific binding was determined in the presence 
of ZM 241385 1 μM. Saturation binding to A2BARs was determined by incubating cell 
membranes (80 g protein/assay) and [
3
H]-MRE 2029F20 (0.01–30 nM) as radioligand 
(specific activity 123 Ci/mmol; GE Healthcare) for 60 min at 4°C. Nonspecific binding 
was determined by using MRE2029F20 1 μM. Saturation binding to A3ARs was 
determined in membranes (80 μg protein/assay) and [3H]-MRE 3008F20 (0.01–30 nM) 
as radioligand (specific activity 67 Ci/mmol; GE Healthcare) at 4°C for 150 min. 
Nonspecific binding was determined in the presence of MRE 3008F20 1 μM. Saturation 
binding experiments were also carried out in untreated or NGF-treated PC12 cells for 
A2AARs and D2DRs in the absence and in the presence of TNF-α (100 ng/ml), CGS 
21680 (1 μM), and SCH 58261 (1 μM). At the end of the incubation time, bound and 
free radioactivity was separated by filtering the assay mixture through Whatman GF/B 
glass fiber filters in a Brandel cell harvester (Brandel, Unterföhring, Germany). Filter 
bound radioactivity was counted in a Packard 2810 TR liquid scintillation counter 
(Packard Instrument Co., Meriden, CT, USA). 
Similar experimental conditions were also carried out in untreated or pharmacologically 
treated PC12 cells with the aim of verifying the affinity and density of D2DRs. 
Experimental condition are summarized in table 4M. 
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Table 4M- Experimental conditions of binding assays for ARs and D2 dopamine receptors. 
  
 
8. Measurement of cAMP levels 
Human lymphocytes or neutrophils (10
6
 cells/sample) were suspended in Krebs Ringer 
phosphate buffer containing 1.0 IU/ml adenosine deaminase and were preincubated for 
10 min in a shaking bath at 37°C. To evaluate the adenylyl cyclase activity and cAMP 
production, the cells were incubated with forskolin (1 μM), adenylate cyclase activator, 
and/or  Ro 20-1724 (0.5 mM) as phosphodiesterase inhibitor. The effect of typical 
A2AAR agonists such as CGS21680 and NECA at different concentrations (1 nM-1 μM) 
was studied. To demonstrate the direct involvement of A2AARs, the effect of a selective 
A2AAR antagonist (SCH 58261, 1 μM) and a nonselective well-known antagonist 
(caffeine, 10 μM) was investigated. The final aqueous solution was tested through a 
competition protein binding assay by using [
3
H]-cAMP (specific activity 21 Ci/mmol; 
GE Healthcare), 0.1 M trizma base, 8.0 mM aminophylline, and 6.0 mM 
mercaptoethanol, pH 7.4. Similar experimental conditions were also used in untreated 
or NGF-treated PC12 cells. 
 
9. Adenosine concentration in human plasma 
Adenosine concentration was evaluated by using a specific sensor that is based on the 
principle of converting adenosine to inosine, hypoxanthine, and uric acid with the 
evolution of hydrogen peroxide. The three enzymes, adenosine deaminase, nucleosidase 
phosphorylase, and xanthine oxidase, required for this process were loaded into single- 
and dual-barrelled sensor probes obtained from Sycopel International (Jarrow, UK). The 
Receptor Radioligand Specific bound [Protein] Time-Temper. 
D2DR 
[
3
H]-Spiperone 
0.05–5 nM 
Butaclamole 
1 μM 
50 μg 
protein/assay 
15 min at 37°C 
A1AR 
[
3
H]-DPCPX 
0.01–20 nM 
DPCPX  
1 μM 
60 μg 
protein/assay 
90 min at 25°C 
A2AAR 
[
3
H]-ZM 241385 
0.01–20 nM 
ZM 241385 
1 μM 
60 μg 
protein/assay 
60 min at 4°C 
A2BAR 
[
3
H]-MRE 2029F20 
 0.01–30 nM 
MRE2029F20  
1 μM 
60 μg 
protein/assay 
60 min at 4°C 
A3AR 
[
3
H]-MRE 3008F20 
 0.01–30 nM 
MRE 3008F20  
1 μM 
80 μg 
protein/assay 
150 min at 4°C  
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probes were controlled by a potentiostat (Biosensor Driver; Sycopel International) that 
held the working electrode at +650 mV to detect hydrogen peroxide. 
 
10.  TNF-α release in human plasma 
TNF-α levels were measured in human plasma obtained from control subjects and PD 
patients by using a highly sensitive human TNF-α enzyme linked immunosorbent assay 
(R&D Systems, Minneapolis, MI, USA) according to the manufacturer’s instructions. 
 
11.  [3H]-dopamine uptake assay 
PC12 cells (10
6
 cells/ml) were suspended in a modified Krebs HEPES buffer containing 
125 mM NaCl, 4.5 mM KCl, 2.2 mM CaCl2, 1.4 mM MgSO4, 1.2 mM KH2PO4, 10 mM 
HEPES, 5.6 mM glucose, 100 μM ascorbic acid, 100 μM pargyline, and 100 nM 
desipramine at pH 7.4. PC12 cells were incubated for 30 min at 37°C with A2AAR 
agonists such as CGS 21680 and NECA or the A2AAR antagonist SCH 58261 and the 
nonselective adenosine antagonist caffeine to evaluate the involvement of A2AARs in 
dopamine uptake. [
3
H]-dopamine (50 nM, specific activity 20.5 Ci/mmol; Perkin Elmer) 
was added to each assay tube, and the cell suspension was incubated for 5 min at 37°C. 
Nonspecific uptake was defined in the presence of the specific dopamine uptake 
inhibitor GBR 12783 (10 μM, Tocris). Uptake experiments were stopped by the 
addition of ice-cold Krebs HEPES buffer and rapid filtration with a Brandel cell 
harvester through Whatman GF/B glass fiber filters. The filter-bound radioactivity was 
counted by using a Packard 2500 TR liquid scintillation counter. 
 
12. Data and statistical analysis 
Dissociation equilibrium constants for saturation binding, affinity, or KD values, as well 
as the maximum densities of specific binding sites (Bmax), were calculated for a system 
of 1-or 2-binding site populations by nonlinear curve fitting using the program Ligand 
(Kell Biosoft, Ferguson, MO, USA). Functional experiments were calculated by 
nonlinear regression analysis using the equation for a sigmoid concentration-response 
curve (GraphPad Prism; GraphPad, San Diego, CA, USA). Analysis of data was 
performed by unpaired t test and differences between the groups were considered 
significant at a value of p<0.01. All experimental data are reported as means ± standard 
error of independent experiments.  
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Differences between groups were analyzed with Dunnett’s test and were considered 
significant at a value of p<0.01. 
A simple regression model was used to analyze the linear dependence of clinical 
variables on Bmax and on the potency (EC50) of typical A2AAR agonists. In addition, 
correlation between pairs of variables was assessed by means of Spearman’s.  
Correlation between continuous variables was verified using Person’s correlation 
coefficient and Spearman’s correlation coefficient and Spearman’s nonparametric 
correlation coefficient. Data were considered statistically significant at p <0.01. 
Variables that are significantly related to Bmax and KD were used as dependent 
variables in multiple regression analyses. To evaluate the relationship between binary 
variables (presence/absence of dyskinesias or motor fluctuation) and binding parameters 
we conducted multivariate logistic regression analyses. Bmax and KD were categorized 
by quartiles, the first quartile being used as a reference category. The estimated odds 
ratios (OR) with 95% confidence interval (CI) were adjusted for age, disease duration 
and the levodopa equivalent daily dose. 
CHAPTER IV-RESULTS 
41 
 
CHAPTER IV  
RESULTS 
IV 
CHAPTER IV-RESULTS 
42 
RESULTS 
1. A2ARs and D2DRs in human putamen 
Figure 1R shows A2AAR and D2DR binding characteristics (affinity and density) in 
human putamen from 7 control and 7 PD postmortem subjects. [
3
H]-ZM 241385 
saturation curves and Scatchard plots show a statistically significant increase of A2AAR 
density in PD subjects of 2.95-fold when compared with controls (Bmax=279±33 and 
822±89 fmol/mg protein respectively; Fig.1R A, B). D2DRs (affinity and density Fig. 
1R C, D) were found in postmortem control subjects and PD patients, revealing the 
presence of a single class of high-affinity D2DRs (KD=0.30±0.004 nM and 0.37±0.06 
nm for control and PD patients respectively) with a low level of expression 
(Bmax=24±3 and 28±4 fmol/mg protein respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1R- Saturation curves and Scatchard plot on human putamen membranes from postmortem 
PD and control subjects of A, B) [
3
H]-ZM 241385 binding to A2AAR and of C, D) 
[
3
H]-spiperone binding to D2DR. Data are expressed as mean ± SE of 7 PD and 7 
control subjects. T-test, *p<0.01 vs. control group. 
 A2AAR D2DR 
KD (nM) Bmax 
(fmol/mg protein) 
KD (nM) Bmax 
(fmol/mg protein) 
Control’s putamen 0.84±0.07 279±33 0.30±0.04 24±3 
PD patients’ putamen 1.23±0.28* 822±89* 0.37±0.06 28±4 
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2. Evaluation of AR mRNA expression and protein level in putamen 
A2AAR mRNA in putamen obtained from control subjects and PD postmortem subjects 
was assayed by using real-time quantitative RT-PCR (Fig. 2R A). An elevated A2AAR 
mRNA increase of 5.2-fold was found in the putamen of PD patients in comparison 
with control subjects (n=7). The immunoblot signals of A2AARs in human putamen 
aliquots of controls and PD patients suggest that A2AARs are differentially expressed in 
healthy humans and in humans with PD (Fig. 2R B). A2AARs proteins are 
overexpressed in PD putamen (280%). These data suggest that the elevated expression 
of A2AAR protein in PD patients is directly associated with an increase in A2AAR 
mRNA.  
 
 
 
 
 
 
 
 
 
 
Fig. 2R- A2AAR mRNA (A) and protein (B) levels in putamen tissues of control and PD 
postmortem subjects. Data are expressed as means± SE. T-test, p<0.01 vs. control 
group. 
 
3. Affinity and density of A1-, A2A-, A2B-, and A3ARs in peripheral blood cells 
Affinity and density of ARs in lymphocyte or neutrophil membranes from the control 
group (n=83) and PD group (n=89) were evaluated. ARs density showed that only 
A2AARs but not A1-, A2B-, and A3ARs were significantly different in PD patients when 
compared with control subjects (Fig. 3R, 4R; Table 2R, 3R). In lymphocyte membranes, 
the affinity of A2AARs was significantly decreased (p<0.01) in PD patients compared 
with control subjects. The density of A2AARs was significantly increased (3.29-fold of 
increase, p<0.01) in the PD group in comparison with the control group (Fig. 4R A, B). 
Similar results were obtained in neutrophil membranes (2.25-fold of increase, p<0.01) 
confirming an alteration of A2AARs in PD patients (Fig. 4R C, D). 
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Fig. 3R - Receptor density of A1-, A2A-, A2B-, and A3ARs in lymphocytes (A) and neutrophils 
(B) from PD patients in comparison with healthy control subjects. Data are expressed 
as means ± SE. T-test, *p < 0.01 vs. control group. 
 
 
 
 
 
 
 
Table 2R- Affinity and density of adenosine receptors in lymphocytes of control subjects and 
PD patients. Data are expressed as means ± SE. T-test, *p < 0.01 vs. control group. 
 
LYMPHOCYTES 
Controls PD Patients 
KD (nM) 
Bmax 
(fmol/mg protein) 
KD (nM) 
Bmax 
(fmol/mg protein) 
[
3
H]-DPCPX 
A1 AR 
1.630.11 343 1.350.06 352 
n=10 n=10 
[
3
H]-ZM 241385 
A2A AR 
1.320.73 5934 2.810.92* 22393* 
n=89 n=83 
[
3
H]-MRE2029F20 
A2B AR 
2.120.15 534 2.160.09 513 
n=10 n=10 
[
3
H]-MRE3008F20 
A3 AR 
1.750.13 1258 1.670.11 1205 
n=10 n=10 
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Table 3R -Affinity and density of adenosine receptors in neutrophils of control subjects and PD 
patients. Data are expressed as means ± SE. T-test, *p < 0.01 vs. control group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUTROPHILS 
Controls PD Patients 
KD (nM) 
Bmax 
(fmol/mg protein) 
KD (nM) 
Bmax 
(fmol/mg protein) 
[
3
H]-DPCPX 
A1 AR 
1.720.13 323 1.710.07 332 
n=60 n=10 
[
3
H]-ZM 241385 
A2A AR 
1.320.08 705 1.960.09* 1607* 
n=60 n=56 
[
3
H]-MRE2029F20 
A2B AR 
2.410.17 785 2.510.08 823 
n=60 n=10 
[
3
H]-MRE3008F20 
A3 AR 
2.320.18 43621 2.570.14 42413 
n=60 n=10 
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Fig. 4R - Saturation curves an Scatchard plot of [
3
H]-ZM 241385 binding to A2AARs on 
lymphocytes (A, B) and neutrophils (C, D) membranes. Data are expressed as means 
± SE. T-test, *p < 0.01 vs. control group. 
 
 
4. Evaluation of AR mRNA expression and protein level in lymphocytes 
AR mRNA in lymphocytes from control subjects and PD patients is reported (Fig. 5R 
A). The mRNA level of A2AARs in PD patients was higher when compared with 
healthy subjects (1.8-fold of increase), while the content of A1-, A2B-, and A3AR mRNA 
in PD (0.8-, 0.9-, and 1.1-fold of increase for A1, A2B, and A3ARs, respectively) was not 
significantly different from healthy subjects, arbitrarily defined as 1. The immunoblot 
signals of A2AARs in lymphocytes of controls and PD patients suggests that A2AARs are 
differentially expressed in healthy humans and in humans with PD (Fig. 5R B). A2AARs 
Lymphocytes 
Neutrophils 
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proteins are overexpressed in lymphocytes (242%) of PD patients when compared with 
control subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5R- A1-, A2A, A2B-, and A3R mRNA in PD patients, calculated as ratio of PD 
patients/healthy subjects (A). Immunoblot and densitometric analysis of A2AARs in 
lymphocytes of PD patients and control subjects. Data are expressed as means± SE. T-
test, *p <0.01 vs. control group. 
 
 
5. Effect of adenosine agonists and antagonists on cAMP assays in blood cells 
In lymphocytes of PD patients and control subjects, there is no change in basal adenylyl 
cyclase activity (18±2 and 17±2 pmol/10
6
 cells, respectively), in the response of the 
direct activator forskolin (73±7 and 72±6 pmol/10
6
 cells, respectively), and in the 
presence of the phosphodiesterase inhibitor Ro 201724 (82±8 and 80±7 pmol/10
6
 cells, 
respectively; Fig. 6R). In a cohort of PD patients and control subjects (n=10 for each 
group), a statistically significant increase of cAMP production by NECA (51±4 and 
38±3 pmol/10
6
 cells, respectively; P<0.01) or CGS 21680 (42±2 and 31±3 pmol/10
6
 
cells, respectively; P<0.01) was found (Fig. 6R). The effect of NECA or CGS 21680 
was evaluated in the presence of SCH58261 (1 μM) or caffeine (10 μM), which reduced 
cAMP levels to control values (in PD patients: 19±2 and 20±2 or 18±2 and 22±2 
pmol/10
6
 cells, respectively; Fig. 6R). In lymphocytes of PD patients, NECA or CGS 
21680 showed EC50 values significantly lower than those in controls, indicating an 
increased potency of 2.2- to 2.1-fold, respectively (Fig. 7R). Maximal cAMP 
accumulation is the stimulatory response obtained by maximal concentration of 
adenosine agonists. In control subjects, NECA (10 μM) and CGS 21680 (10 μM) 
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mediated an increase of cAMP production reaching values of 100±7 and 112±8 
pmol/10
6
 cells, respectively. 
In PD patients, NECA or CGS 21680 at 5 μM concentrations increased cAMP levels to 
98±6 and 105±7 pmol/10
6
 cells, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6R- Effect of forskolin (1 μM) in the absence and in the presence of Ro 201724 (0.5 mM), 
NECA (100 nM), and CGS 21680 (100 nM) in the absence and in the presence of 
SCH 58261 (1 μM) and caffeine (10 μM) on the stimulation of cAMP levels in 
lymphocytes obtained from controls (n=10) and PD patients (n=10). Data are 
expressed as means ± SE. 1-way ANOVA with Dunnett’s post hoc test, *p < 0.01 
vs. basal levels.  
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Fig. 7R- NECA (A) and CGS 21680 (B) concentration response curves on cAMP accumulation 
in lymphocytes obtained from controls (n=10) and PD patients (n=10). Data are 
expressed as means ± SE.  
 
 
6. TNF-α concentration in plasma from PD patients 
Basal levels of TNF-α were measured in plasma from control subjects (31±3 pg/ml) and 
PD patients (92±8 pg/ml). A marked increase of  TNF-α concentration was observed in 
plasma PD patients when compared with healthy volunteers (Fig. 7R). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7R- TNF-α levels in plasma of the examined subjects ( n=6 for each group). Data are 
expressed as means ± SE. T-test, *p < 0.01 vs. control group. 
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7. Adenosine concentration in human plasma from PD patients 
Preliminary experiments were conducted to calibrate the potentiostat and the associated 
sensors. A buffer containing various concentrations of adenosine was used to evaluate 
the change in current from the baseline and to obtain a calibration curve with a high 
correlation coefficient (r=0.99). 
Figure 8R shows the concentration of adenosine and adenosine metabolites represented 
by inosine and hypoxanthine in control subjects and PD patients. Adenosine metabolite 
concentrations in the micromolar range were significantly higher in PD patients 
(5.1±0.4 μM) than in controls (2.0±0.2 μM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8R- Adenosine, inosine, and hypoxanthine concentrations in plasma of the examined 
subjects (n= 6 for each group). Data are expressed as means ± SE. T-test, *p < 0.01 
vs. control group. 
 
 
8. Correlation between A2AAR binding parameters or functional data and 
clinical characteristics 
 
In our statistical analysis no differences in A2AAR parameters across different age, age 
at onset or disease duration was found. Correlation analyses show that Bmax and KD of 
the A2AAR correlate with severity of PD symptoms. A direct correlation was found 
between UPDRS motor score and A2AAR binding parameters (Bmax and KD) and an 
inverse correlation with functional data (EC50) in lymphocytes and neurophils of PD 
patients (table 4R; fig. 9R). A very high correlation between UPDRS (total score and 
part I, II, III, and IV score) and A2AAR density was detected. The strongest correlation 
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was found with UPDRS III: the correlation coefficient with Bmax reaches a value of 
r=0.515 (p<0.0001) and of r=0.58 (p<0.0001) with KD. Although A2AAR density and 
affinity don’t appeare to increase with increasing Hoehn and Yahr stage, (p=0.14 and 
p=0.09 respectively). The correlation between UPDRS part IV score and A2AAR 
binding parameters was stronger when considering only items 32-39 that assessed 
dyskinesias and motor fluctuations. MMSE that concern the global cognitive status 
show a negative correlation with Bmax values (r=-0.25) and the affinity of the A2AAR 
decreased with decreasing MMSE score (r=-0.42). Any significant correlation was 
found with GDS and FAB score (table 5R). Variable that were found to be significantly 
related to Bmax and KD values were submitted in multiple regression analyses 
confirming the relationships showed by the previous analysis (Table 6R). In PD patients 
with dyskinesias the A2AAR density was significantly higher (p<0.005) and the affinity 
lower (p<0.0001) than in patients without these complications (Bmax=265±102 and 
187±70 fmol/mg protein respectively). Patients with motor fluctuations have A2AAR 
density significantly higher and a lower affinity. 
The multivariate logistic regression analysis shows that patients above the upper 
quartile had an increased odds to suffer from dyskinesias as compared to patients in the 
lowest quartile while patients with Bmax above the median had a 3.7 times higher odds 
to suffer from dyskinesias. Similar results were found when analyzing the relationship 
between Bmax and motor fluctuations.    
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Fig. 9R - Linear regression analysis between UPDRS motor score and maximum number of 
A2AARs (Bmax) in lymphocytes and neutrophils. Similar correlation was also 
evaluated between UPDRS motor score and A2AAR agonists such as NECA and 
CGS 21680 potency (EC50) in lymphocytes and neutrophils. 
 
 
LYMPHOCYTES 
 
NEUTROPHILS 
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Table 4R- Correlation between UPDRS motor score and A2AARs density (Bmax) or functional 
(EC50) parameters in lymphocytes and neutrophils. 
 
 
Table 5R- Correlation analysis between clinical variables and A2AAR affinity (KD) or density 
(Bmax). R, Pearson correlation coefficient; UPDRS IV*, item 32-39.  
 
A2AAR parameters 
UPDRS motor score 
Linear regression 
UPDRS motor score 
Spearman coefficient 
 r P-value ρ P-value 
 L 
Y 
M 
P 
H 
O 
C 
Y 
T 
E 
S 
Bmax (fmol/mg protein) 0.5162 <0.0001 0.4725 0.0002 
EC50 (NECA, nM) 0.5919 0.0009 -0.4916 0.0079 
EC50 (CGS 21680, nM) 0.5940 0.0009 -0.5584 0.0020 
N 
E 
U 
T 
R 
O 
P 
H 
I 
L 
S 
Bmax (fmol/mg protein) 0.5429 <0.0001 0.4837 0.0002 
EC50 (NECA, nM) 0.6407 0.0002 -0.5049 0.0061 
EC50 (CGS 21680, nM) 0.6265 0.0004 -0.6673 0.0001 
Demographic and PD 
Characteristics 
Bmax 
r 
KD 
r 
Age 0.185 0.096 
Age at onset 0.16 0.033 
Duration since onset 0.08 0.123 
UPDRS I 0.42 (P<0.0001) 0.31 (P<0.005) 
UPDRS II 0.48 (P<0.0001) 0.397 (p<0.0001) 
UPDRS III 0.515 (P<0.0001) 0.58 (P<0.0001) 
UPDRS IV 0.326 (P>0.005) 0.35 (P<0.001) 
UPDRS IV* 0.49 (P<0.0001) 0.48 (P<0.001) 
UPDRS Total 0.53 (p<0.0001) 0.55 (P<0.0001) 
MMSE -0.25 (P<0.005) -0.42 (P<0.0001) 
FAB -0.212 -0.17 
GDS 0.18 0.143 
LEDD 0.25 -0.01 
CHAPTER IV-RESULTS 
54 
Clinical variable 
Bmax, fmol/mg protein 
Beta (P value) 
Kd, nM 
Beta (P value) 
UPDRS I 0.39 (<0.0001) 0.31 (<0.001) 
UPDRS II 0.44 (<0.0001) 0.35 (<0.005) 
UPDRS III 0.46 (<0.0001) 0.47 (<0.0001) 
UPDRS IV 0.30 (<0.0001) 0.23 (<0.05) 
UPDRS IV (items 32-39) 0.38 (<0.0001) 0.29 (<0.005) 
UPDRS total 0.49 (<0.0001) 0.46 (<0.0001) 
MMSE -0.3 (<0.01) -0.35 (<0.005) 
 
Table 6R - Regression coefficients (multiple regression analysis) between A2AAR affinity (KD, 
nM) and density (Bmax, fmol/mg protein) and clinical variable.   
 
 
 
 
 
 
 Dyskinesias 
OR (95% CI)* 
Motor fluctuations 
OR (95% CI)* 
Bmax upper vs lowest 
quartile 
16.9 (4-71.3) 6.4 (1.9-21.5) 
Bmax above the median 
vs lowest quartile 
3.7 (1.4-9.8) 3.2 (1.1-8.8) 
Kd upper vs lowest 
quartile 
3.86 (1.2-12.5) 1.95 (0.9-5.37) 
Kd above the median vs 
lowest quartile 
2.4 (1.04-5.88) 1 (0.39-2.6) 
 
Table 7R - Multivariate logistic regression analyses of binding parameters and 
dyskinesia/motor fluctuations. *OR adjusted for age, disease duration and 
LEDD. 
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9. Adenosine and dopamine binding experiments in PC12 cells 
The presence of A1-, A2A-, A2B-, and A3ARs and D2DRs in untreated or NGF-treated 
PC12 cells is shown (Fig. 10R). NGF treatment did not modify the affinity and/or 
density of ARs or DRs. The effect of TNF-α in A2AAR saturation binding experiments 
revealed a significant increase of A2AAR density of 2-fold in untreated or NGF-treated 
PC12 cells (Bmax=7.8±0.7 fmol/10
6
 cells and 15.8±1.6 fmol/10
6
 cells respectively 
before and after TNF-α treatment; Fig. 11R). This proinflammatory cytokine did not 
affect the affinity and density of D2DRs (Fig. 11R). In untreated or NGF-treated PC12 
cells, CGS 21680 (1 μM) mediated a statistically significant decrease of A2AAR and 
D2DR density. Interestingly, the presence of SCH 58261 (1 μM) mediated an up-
regulation of A2AARs and D2DRs of 1.8- to 1.9-fold and 1.5- to 1.6-fold in comparison 
with controls, respectively (Fig. 12R). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10R- A1-, A2A-, A2B-, and A3AR density (Bmax, fmol/10
6
 cells) in untreated or NGF-
treated PC12 cells. Data are expressed as means±SE.  
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Fig. 11R- Effect of TNF-α (100 ng/ml) on A2AAR density in untreated or NGF-treated PC12 
cells. Data are expressed as means ± SE. T-test, *p <0.01 vs. control group. 
 
 
 
 
 
Untreated PC12 cells NGF-treated PC12 cells 
[
3
H]-ZM241385 
A2AAR 
[
3
H]-Spiperone 
D2DR 
[
3
H]-ZM241385 
A2AAR 
[
3
H]-Spiperone 
D2DR 
Control 
KD=1.85±0.19 nM 
 
Bmax=7.2±0.8 
fmol/10
6
 cells 
KD=0.72±0.08 nM 
 
Bmax=6.0±0.6 
fmol/10
6
 cells 
KD=1.84±0.21 nM 
 
Bmax=7.8±0.7 
fmol/10
6
 cells 
KD=0.76±0.06 nM 
 
Bmax=6.5±0.5 
fmol/10
6
 cells 
TNF-α 
treatment 
100 ng/ml 
KD=1.95±0.16 nM 
 
Bmax=14.6±1.3* 
fmol/10
6
 cells 
KD=0.72±0.06 nM 
 
Bmax=6.2±0.6 
fmol/10
6
 cells 
KD=1.91±0.18 nM 
 
Bmax=15.8±1.6* 
fmol/10
6
 cells 
KD=0.68±0.07 nM 
 
Bmax=6.7±0.6 
fmol/10
6
 cells 
CGS21680 1µM 
KD=1.88±0.17 nM 
 
Bmax=4.1±0.4* 
fmol/10
6
 cells 
KD=0.71±0.08 nM 
 
Bmax=3.7±0.4* 
fmol/10
6
 cells 
KD=1.93±0.19 nM 
 
Bmax=4.4±0.4* 
fmol/10
6
 cells 
KD=0.74±0.07 nM 
 
Bmax=3.9±0.3* 
fmol/10
6
 cells 
SCH58263 1µM 
KD=1.87±0.18 nM 
 
Bmax=12.8±1.1* 
fmol/10
6
 cells 
KD=0.76±0.08 nM 
 
Bmax=9.2±0.6 
fmol/10
6
 cells 
KD=1.85±0.17 nM 
 
Bmax=14.9±1.7* 
fmol/10
6
 cells 
KD=0.73±0.06 nM 
 
Bmax=10.6±0.8* 
fmol/10
6
 cells 
 
 
 
Table 8R- Effect of TNF-α, CGS21680 and SCH58261 in PC12 cells on affinity and density of 
A2AARs and D2DRs. Data are expressed as mean ± SE. T-test, *p <0.01 vs. control 
group. 
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10. cAMP assays in PC12 cells 
In untreated or NGF-treated PC12 cells, forskolin increased basal cAMP levels of 3.1- 
and 3.0-fold, respectively. The modulation of cAMP production by the adenosine 
agonists NECA and CGS 21680 was investigated in the absence and in the presence of 
TNF-α (Fig. 12R). NECA and CGS 21680 increased the basal adenylyl cyclase activity 
by 2.1- and 1.9-fold, respectively. The presence of TNF-α mediated a significant 
increase of NECA- and CGS 21680-stimulated cAMP production at the 100 nM 
concentration in untreated or NGF-treated PC12 cells (Fig. 12R). In PC12 cells, NECA 
and CGS 21680 showed a high potency in cAMP production, with an EC50 of 115 ± 12 
and 159 ±14 nM, respectively. The pretreatment of TNF-α caused an increase of NECA 
and CGS 21680 potency (EC50 63±6 and 78±8 nM, respectively; p<0.01 vs. control 
condition) that correlated closely with the increase in A2AAR density. Analogous results 
were also obtained in NGF-treated PC12 cells (Fig. 13R). The selective A2AAR 
antagonist SCH 58261 (1 μM) completely abrogated the stimulatory effect of adenosine 
agonists. Similarly, caffeine (10 μM) reduced NECA or CGS 21680-induced cAMP 
stimulation in NGF treated PC12 cells before and after TNF-α treatment (Fig. 12R). In 
NGF-treated PC12 cells, NECA (10 μM) and CGS 21680 (10 μM) mediated an increase 
of cAMP production reaching values of 98± 6 and 95± 5 pmol/10
6
 cells, respectively. 
After treatment with TNF-α, NECA or CGS 21680 at 5 μM increased cAMP production 
to 106 ± 7 and 100 ± 6 pmol/10
6
 cells, respectively (Fig. 13R A, B). 
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Fig. 12R- Effect of forskolin (1 μM) in the absence and in the presence of Ro 201724 (0.5 mM), 
NECA (100 nM), and CGS 21680 (100 nM) in the absence and in the presence of 
SCH 58261 (1 μM) and caffeine (10 μM) on the stimulation of cAMP levels in 
NGF-treated PC12 cells before and after TNF-α treatment. Data are expressed as 
means ± SE. 1-way ANOVA with Dunnett’s post hoc test, *p < 0.01 vs. basal levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13R- NECA (A) and CGS 21680 (B) concentration response curves on cAMP accumulation 
in NGF treated PC12 cells before and after TNF-α treatment. Data are expressed as 
means ± SE. 
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Effect of A2A agonist/antagonist on dopamine uptake in PC12 cells 
Dopamine uptake in PC12 cells was investigated in the absence and in the presence of 
NECA (1 μM) and CGS21680 (1 μM). A2AAR agonists caused a statistically significant 
increase of dopamine uptake of 1.6- to 1.7-fold in comparison with untreated PC12 
cells. Similarly, in NGF-treated PC12 cells, NECA and CGS 21680 increased dopamine 
uptake by 62 and 70%, respectively. A selective A2AAR antagonist (SCH 58261, 10 
μM) blocked the increased dopamine uptake induced by the adenosine agonists. 
Similarly, caffeine (10 μM) abrogated NECA and CGS 21680 stimulatory effects (Fig. 
14R A, B). 
 
 
 
Fig. 14R - Dopamine uptake in the absence and in the presence of typical adenosine agonists 
NECA (1 μM) and CGS 21680 (1 μM) or of adenosine antagonists SCH 58261 (10 
μM) and caffeine (10 μM) in untreated (A) or NGF-treated (B) PC12 cells. Data are 
expressed as means ± SE. 1-way ANOVA with Dunnett’s post hoc test, *p < 0.01 
vs. basal levels.  
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DISCUSSION AND CONCLUSIONS 
Chronic administration of L-DOPA, the gold standard treatment for PD, leads to abnormal 
motor responses known as dyskinesias involving involuntary choreic or dystonic movements 
in 50% of patients in 5 years after the initiation of treatment [163]. Fifty years after its 
introduction, L-DOPA remains the most effective form of oral symptomatic treatment for 
motor symptoms. There are three form of dyskinesias that commonly occur with L-DOPA 
use: peak dose dyskinesia, diphasic dyskinesia at the end of L-DOPA efficacy and off-period 
dystonia when a patient receives subtherapeutic levels of L-DOPA [164]. Actually researchers 
are focused on the study of A2AAR like an alternative therapeutic target to use it alone or in 
combination to L-DOPA with the purpose to avoid side effects. These researchers are 
supported by an important evidence of A2AAR involvement in PD due to an antagonistic 
effects on D2DRs [165]. 
From our study emerges an increase of A2AARs on putamen membranes associated to an 
increase of mRNA levels and proteins in respect to the putamen of control subjects. However 
there is any difference in D2DRs expression in PD patients putamen compare to controls. This 
data confirm the key role of A2AARs in neurological diseases and are conform with previous 
studies demonstrating the selective distribution of A2AAR mRNA in the caudate-putamen and 
the increase of A2AAR transcript in PD patients. However literature data are in contrast with 
our binding results because did are not found any differences in [
3
H]-CGS21680 binding site 
to A2AAR in the striatum and pallidum of PD patients when compared with controls. A 
possible explanation of these differences could be due to the characteristics of radioligand 
used (agonist versus antagonist). In CHO cells stably transfected with the human A2AAR, the 
Bmax value, calculated using the antagonist [
3
H] CGS21680, was twice as high as that found 
when was used the agonist [
3
H] SCH58261, because the agonist radioligand only binds to 
receptors present in the high-affinity state [166]. With this premise we sustain that agonist 
radioligand label only the active adenosine binding site hampering the identification of all 
A2AARs. As a consequence, it has been suggested that in human tissues adenosine antagonists 
are better for characterizing A2AAR of both active and inactive status. Our experimental data 
reveal that the increased A2AARs density is associated with and enhanced stimulation of 
cAMP production suggesting an increase of the active form of the receptor. Moreover the 
evaluation of adenosine concentration and its metabolites in human plasma shows that 
adenosine levels are increase in PD patients. There are many reports in literature showing that 
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the physiological effects of adenosine, which include regulation of cytokines production, are 
mediated by binding to cell surface ARs regulating the anti-inflammatory response.  
In previous studies elevated levels of proinflammatory cytokines such as TNF-α in the 
striatum of PD brains have been found. Enhanced expression of TNF-α has been shown in the 
cerebrospinal fluid as well as in the basal ganglia of PD patients. The presence of elevated 
levels of cytokines seems to amplify and sustain the neuroinflammation as well as further 
consequent immune responses leading to irreversible destruction of dopaminergic neurons. 
How expected TNF-α levels in plasma of PD patients that we analyzed are much more 
elevated than in healthy controls suggesting an inflammatory status in PD. 
TNF-α is able to increase A2AAR mRNA and proteins in different A549 lung epithelial cell 
line [167], peripheral blood mononuclear cells [168] and polymorphonuclear neutrophils 
[169]. Then we suppose that high levels of TNF-α are able to drive the overexpression of 
A2AAR in brain of PD patients.  
To investigate the role of TNF-α in A2AAR expression we use pheochromocytoma cells 
(PC12), a widely useful cell line for the study of neurobiological mechanisms. No difference 
were found for ARs and D2DR in untreated or NGF-treated PC12 cells, suggesting that the 
treatment for the cell differentiation did not modify the receptor binding and functional 
parameters. TNF-α in PC12 cells determined an increase of A2AARs but not D2DRs, 
suggesting that high levels of this cytokine could be one of the causes of A2AAR upregulation 
in PD. In addition TNF-α mediates an increase in A2AAR functionality, as demonstrated by 
cAMP production: intensified antagonistic interaction with dopaminergic signaling could be 
explain by the opposite effect exerted on second messenger production. 
The direct involvement of A2AAR in dopamine uptake was investigated. CGS21680 and 
NECA, selective and unselective A2AAR agonists, increased dopamine uptake, reducing the 
dopamine concentration active in the receptor sites. A good agreement was found between 
cAMP accumulation and dopamine uptake, suggesting that the effect of adenosine agonists 
could be mediated by a molecular pathway involving cAMP. Inhibition of dopamine uptake in 
PD could provide symptoms improvement, an effect that could be mediated by A2AAR 
antagonists.  
We focused our research also in the identification of a possible new biomarker for PD 
diagnosis and disease progression. In our study we found a strong correlation between A2AAR 
alteration, in lymphocytes and neutrophils, and PD severity as indexed by UPDRS motor 
score: PD patients having an higher UPDRS motor score also exhibit an increase in A2AAR 
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density. This suggest that the disease severity is closely associated with the increase of 
A2AAR. Our data revealed also an high inverse correlation between cognitive performance as 
approximated by the MMSE and A2AAR density and affinity.  
Interestingly we found a significantly different A2AAR profile in PD patients with and without 
levodopa-induced motor complications independent on  age, disease duration and medication.  
Studies on animal models of dyskinesia show that A2AAR plays a critical role in the 
development and persistence of complications induced by repeated levodopa treatments. 
From experiments in 6-OHDA lesioned mice, WT and A2AAR-KO, treated with a low dose of 
L-DOPA, emerges that A2AAR is required for the development and persistence of L-DOPA-
induced behavioral sensitization [163]. Moreover the increase of A2AAR mRNA (+60%) was 
found in dyskinetic patients compared with non-dyskinetic PD patients in the lateral putamen 
[153].  
These results demonstrate that A2AAR antagonist could be an useful target for PD therapy by 
inhibiting dopamine uptake representing a novel pharmacological strategy based on the 
A2A/D2 interaction.  
In our opinion a sustained exposition to an inflammatory stimuli and a consequent massive 
release of TNF-α in the brain could induce an hyper-expression of A2AARs by activation of 
the nuclear factor NF-kB, mediating the well known effect on D2DRs also through an 
antagonism on the second messenger production and cAMP production. This effect and the 
increase of dopamine up-take after A2AAR stimulation (with a consequent reduction of 
dopamine to receptorial sites), could be the mechanism mediating the motor impairment in 
PD patients. 
According to National Institutes of Health a biomarker is a “characteristic that is objectively 
measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”. A good molecular biomarker for PD 
could help to identify at-risk individuals, to detect the disease at early stages, improving 
diagnostic accuracy and prognosis [170]. In our study A2AAR alterations in peripheral blood 
cells demonstrated several characteristics that make them attractive as a possible biomarker of 
PD. They can be evaluated through a non-invasive blood examination, easily acceptable even 
for repeated tests. Moreover the relationship between A2AAR density and affinity seems to be 
independent from demographic characteristics, disease duration and antiparkinsonian drugs. 
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Fig. 1D – Possible A2AAR molecular mechanism inducing motor impairment.
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 UPDRS 
Sezione I 
ATTI VITA' PSICHICA, 
COMPORTAMENTO E TONO DELL’UMORE 
Alterazione delle facoltà intellettuali 
0. Nessuna. 
1. Lieve dimenticanza consistente in ricordo parziale 
di 
accadimenti, senza altre difficoltà. 
2. Modesta perdita di memoria, con disorientamento 
e moderata difficoltà a trattare problemi complessi. 
Lieve ma moderato peggioramento delle funzioni 
domestiche con necessità di suggerimento 
occasionale. 
3. Perdita di memoria severa con disorientamento nel 
tempo e spesso nello spazio. Peggioramento severo a 
trattare problemi. 
4. Perdita di memoria severa con orientamento 
conservato solo alla persona. Incapacità ad emettere 
giudizi o a risolvere problemi. Richiede molto aiuto 
nella cura della persona. Non può essere lasciato da 
solo. 
 
Alterazioni del pensiero 
0. Nessuna. 
1. Immaginazione fervida. 
2. Allucinazioni “benigne” con interiorizzazione. 
3. Allucinazioni o delusioni da occasionali a frequenti; 
senza interiorizzazione, possibile interferenza col 
quotidiano. 
4. Allucinazioni permanenti, delusione o psicosi 
floride. Non in grado di badare a sé stessi. 
 
Depressione 
0. Assente. 
1. Periodi di tristezza odi senso di colpa maggiori del 
normale, non sostenuto mai per giorni o settimane. 
2. Depressione sostenuta (i settimana o più). 
3. Depressione sostenuta con sintomi vegetativi 
(insonnia, anoressia, calo ponderale, caduta 
dell’interesse). 
4. Depressione sostenuta con sintomi vegetativi e 
pensieri o tentativi suicidi. 
 
Motivazione/iniziativa 
0. Normale. 
1. Meno affermativa del normale. 
2. Perdita dell’iniziativa o disinteresse in attività 
elettive (non routinarie). 
3. Perdita dell’iniziativa o disinteresse nel quotidiano 
(routine). 
4. Isolamento, completa perdita della motivazione. 
 
 
 
 
Sezione II 
ATTIVITÀ DI VITA QUOTIDIANA 
(DETERMINARE PER FASI ON/OFF) 
Linguaggio 
0. Normale. 
1. Lievemente interessato; nessuna difficoltà ad essere 
compreso. 
2. Moderatamente interessato; qualche volta 
richiesta la 
ripetizione delle affermazioni. 
3. Severamente interessato; frequentemente 
richiesta la 
ripetizione delle affermazioni. 
4. Incomprensibile per la maggior parte del tempo. 
 
Salivazione - 
0. Normale. 
1. Lieve ma definito eccesso di saliva nella bocca; può 
presentare sbavamento notturno. 
2. Saliva moderatamente in eccesso; può presentare 
sbavamento minimo. 
3. Marcato eccesso di saliva con qualche sbavamento. 
4. Marcato sbavamento, richiede costante 
ripulimento. 
 
Deglutizione 
0. Normale. 
1. Soffocamento raro. 
2. Soffocamento occasionale. 
3. Richiede cibi delicati. 
4. Richiede alimentazione attraverso sondino naso 
gastrico o gastrostomia. 
 
Scrittura 
0. Normale. 
1. Leggermente lenta o piccola. 
2. Moderatamente lenta o piccola; tutte le parole 
sono leggibili. 
3. Gravemente colpita; non tutte le parole sono 
leggibili. 
4. La maggior parte delle parole non sono leggibili. 
 
Taglio dei cibi e manualità degli utensili 
0. Normale. 
1. Piuttosto lento e goffo, ma non necessita di aiuto. 
2. Può tagliare la maggior parte dei cibi, anche se 
goffamente e lentamente; necessita di qualche aiuto. 
3. I cibi devono essere tagliati da qualcuno. ma può 
ancora alimentarsi lentamente. 
4. Necessità di essere alimentati. 
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Il vestirsi 
0. Normale. 
1. Piuttosto lento, ma non necessita di aiuto. 
2. Assistenza occasionale nell’abbottonamcnto e 
nell’infilare le braccia nelle maniche. 
3. Richiesto aiuto considerevole, ma può compiere 
qualche movimento da solo 
4.incapacità 
 
Igiene personale 
0. Normale. 
1. Piuttosto lenta, ma non necessita di aiuto. 
2. Necessita di aiuto per la doccia o il bagno; molto 
lenta 
l’igiene personale. 
3. Assistenza richiesta per le operazioni di lavaggio: 
usare lo spazzolino per i denti, asciugatura dei capelli, 
andare in bagno 
4. Cateteri di Foley o altri supporti meccanici. 
 
Girarsi nel letto o aggiustarsi le coperte 
0. Normale. 
1. Piuttosto lento e goffo, ma non necessita di aiuto. 
2. Può girarsi da solo o aggiustarsi le coperte, ma con 
grande difficoltà. 
3. Può tentare, ma non girarsi o aggiustarsi le coperte 
da solo. 
4. Incapacità. 
 
Caduta (non collegata a freezing) 
0. Nessuna. 
1. Cadute rare. 
2. Cadute occasionali, meno di una al giorno. 
3. Cadute, in media una al giorno. 
4. Cadute, molte più di una al giorno. 
 
Freezing durante la marcia 
0. Nessuna. 
1. Freezing raro durante la marcia; può avere avvio 
esitante. 
2. Freezing occasionale durante la marcia. 
3. Freezing frequente; occasionalmente caduta per 
freezing. 
4. Cadute frequenti per freezing. 
 
Marcia 
0. Normale. 
1. Leggera difficoltà; può non oscillare le braccia o 
può trascinare le gambe.  
2. Difficoltà moderata, ma richiede poca o nessuna 
assistenza. 
3. Grave disturbo del moto, richiede assistenza. 
4. Non può completamente camminare, anche con 
assistenza. 
 
Tremore 
0. Assente 
1. Fine ed infrequentemente presente. 
2. Moderato; fastidioso per il paziente. 
3. Severo; interferisce con molte attività. 
4. Marcato; interferisce con la maggior parte delle 
attività. 
 
Disturbi sensoriali collegati ai parkinsonismi 
0. Nessuno. 
1. Occasionalmente presenta intorpidimetnto, 
formicolio 
o lieve dolore. 
2. Frequentemente presenta intorpidimento, 
formicolio o 
dolore; non angoscioso. 
3. Frequente sensazione dolorosa. 
4. Dolore straziante. 
 
Sezione III 
ESAME DELLA MOTRICITÀ 
Linguaggio 
0. Normale. 
1. Lieve perdit;~ dell’espressione, della dizione e/o 
del 
volume. 
2. Monotono. disarticolato ma comprensibile; 
moderatamente peggiorato. 
3. Marcato peggioramento, difficoltà a comprendere. 
4. Incomprensibile 
 
Espressione del volto 
0. Normale. 
1. lpomimia minimale, potrebbe essere normale 
amimia. 
2. Lieve ma definita diminuzione dell’espressione 
facciale. 
3. Moderata ipomimia; labbra dischiuse per buona 
parte del tempo. 
4. Volto immobile a maschera, con severa o completa 
perdita dell’espressività del volto; labbra dischiuse 
poco o molto. 
 
Tremore a riposo 
0. Assente. 
1. Fine ed infrequentemente presente. 
2. Leggero nell’ampiezza e persistente. Oppure 
moderato nell’ampiezza ma solo intermittentemente 
presente. 
3. Moderato nell’ampiezza e presente per la maggior 
parte del tempo. 
4. Marcato nell’ampiezza e presente per la maggior 
parte del tempo. 
 
Attività o tremore posturale delle mani 
0. Assente. 
1. Fine; presente con l’attività. 
2. Moderato nell’ampiezza, presente con l’attività. 
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3. Marcato, ma l’intero range dei movimenti si compi 
con facilità. 
4. Severo, il range dei movimenti si compie con 
difficoltà. 
 
Rigidità (valutata sui movimenti passivi delle 
articolazioni maggiori a paziente rilassato in 
posizione seduta. Ignorare i movimenti a 
scatti) 
0. Assente. 
1. Leggera o identificabile solo quando attivata allo 
specchio o da altri movimenti. 
2. Da lieve a moderata. 
3. Marcata, ma range completo di motricità compiuto 
facilmente. 
4. Severa, range di motricità compiuto con difficoltà. 
 
Picchiettamento delle dita (il paziente 
picchietta il pollice contro il dito indice in 
rapida successione con la massima ampiezza 
possibile, separatamente per ciascuna 
mano) 
0. Normale 
1. Leggermente rallentato e/o ridotta l’ampiezza. 
2. Moderatamente indebolito. Determinato e 
rapidamente 
faticoso. Può presentare arresto occasionale del 
movimento. 
3. Severamente indebolito. Frequente esitazione 
nell’iniziare il movimento oppure arresto del 
movimento in corso. 
4. Può a malapena eseguire il compito. 
 
Movimento delle mani ( il paziente apre e 
chiude le mani in rapida successione con la 
massima ampiezza possibile,separatamente 
per ciascuna mano) 
0. Normale. 
1. Leggermente rallentato e/o ridotta l’ampiezza. 
2. Moderatamente indebolito. Determinato e 
rapidamente faticoso. Può presentare arresto 
occasionale del movimento. 
3. Severamente indebolito. Frequente esitazione 
nell’iniziare il movimento oppure arresto del 
movimento in corso. 
4. Può a malapena eseguire il compito. 
 
Rapidi movimenti alternati delle mani 
(movimenti di pronazione-supinazione delle 
mani, verticalmente o orizzontalmente, con 
un’ampiezza tanto larga quanto possibile, 
con 
entrambe le mani simultaneamente) 
0. Nornali. 
1. Leggermente rallentati e/o ridotta l’ampiezza. 
2. Moderatamente indeboliti. Determinato e 
rapidamente faticoso. Può presentare arresto 
occasionale del movimento. 
3. Severamente indeboliti. Frequente esitazione 
nell’iniziare il movimento oppure arresto del 
movimento in corso. 
4. Può a malapena eseguire il compito. 
 
Agilità delle gambe ( il paziente batte il 
tallone sul pavimento in rapida successione, 
alzando l’intera gamba. L’ampiezza dovrebbe 
essere di circa 8 cm) 
0. Normale. 
1. Leggermente rallentata e/o ridotta l’ampiezza. 
2. Moderatamente indebolita. Determinata e 
rapidamente faticosa. Può presentare arresto 
occasionale del movimento. 
3. Severamente indebolita. Frequente esitazione 
nell’iniziare il movimento oppure arresto del 
movimento in corso. 
4. Può a malapena eseguire il compito. 
 
Alzarsi dalla sedia (il paziente tenta di alzarsi 
da una sedia a schienale dritto di legno o di 
metallo, con le braccia incrociate sul torace) 
0. Normale. 
1. Lento o può necessitare di più di un tentativo. 
2. Si dà la spinta mediante i braccioli della sedia 
3. Tende a ricadere indietro e può dover tentare più 
di una volta, ma può alzarsi senza aiuto. 
4. Incapace di alzarsi senza aiuto. 
 
Postura 
0. Normale eretta. 
1. Non completamente eretta, postura leggermente 
chinata; potrebbe essere normale per le persone 
anziane. 
2. Postura moderatamente chinata, francamente 
anormale; può essere moderatamente inclinata su di 
un lato. 
3. Postura severamente chinata con cifosi; può essere 
moderatamente inclinata su di un lato. 
4. Marcata flessione con estrema anormalità della 
postura. 
 
Andatura 
0. Normale. 
1. Cammina lentamente, può trascinarsi a piccoli 
passi, ma senza festinazione o spinta. 
2. Cammina coh difficoltà, ma richiede poca o 
nessuna assistenza; pùò presentare qualche 
festinazione, passi piccoli o spinta. 
3. Severo disturbo dell’andatura; richiede assistenza. 
4. Non può camminare affatto, eventualmente con 
assistenza. 
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Stabilità posturale ( risponde al rapido 
spostamento indietro prodotto dalla trazione 
sulle spalle a paziente eretto con gli occhi 
aperti ed i piedi lievemente distanziati) 
0. Normale. 
1. Retropulsione, ma compensa senza aiuto. 
2. Assenza di risposta posturale; potrebbe cadere se 
non sorretto dall’esaminatore. 
3. Molto instabile, tende a perdere l’equilibrio 
spontaneamente. 
4. Incapace di rimanere in piedi senza assistenza. 
 
Bradicinesia ed ipocinesia corporea 
(combinante lentezza, esitazione, diminuita 
oscillazione delle braccia, ampiezza ridotta e 
povertà dei movimenti in generale) 
0. Nessuna. 
1. Lentezza minimale, conferendo movimento ad un 
carattere voluto, potrebbe essere normale per alcune 
persone. Possibilmente ridotta ampiezza. 
2. Lieve grado di lentezza e povertà di movimenti che 
è francamente anormale. Alternativamente, una certa 
riduzione d’ampiezza. 
3. Moderata lentezza, povertà o limitata ampiezza del 
movimento. 
4. Marcata lentezza, povertà o limitata ampiezza del 
movimento. 
 
Sezione IV 
COMPLICANZE DELLA TERAPIA 
(NELLA SETTIMANA TRASCORSA) 
A. DISCINESIE 
Durata: in che percentuale si presentano le 
discinesie durante lo stato di veglia? 
(informazioni anamnestiche) 
0. Nessuna. 
1. 1—25% della giornata. 
2. 26—50% della giornata. 
3. 51—75% della giornata. 
4. 76-100% della giornata. 
 
Invalidità: quanto invalidanti sono le 
discinesie? (informazioni anamnestiche; 
possono essere modificate attraverso 
l’accertamento d’ufficio) 
0. Non invalidanti. 
1. Lievemente invalidanti. 
2. Moderatamente invalidanti. 
3. Severamente invalidanti. 
4. Completamente invalidanti. 
 
Discinesie dolorose: quanto dolorose sono le 
discinesie? 
0. Assenza di discinesie dolorose. 
1. Lievi. 
2. Moderate 
3. Severe. 
4. Marcate. 
 
Presenza di distonia mattutina (notizie 
anamnestiche) 
0. No 
1. Si 
 
B OSCILLAZIONE CLINICA 
Ci sono dei periodi prevedibili di "off” come a 
determinare il tempo successivo ad una dose 
di farmaco? 
0. No. 
1. SÌ. 
 
Ci sono dei periodi imprevedibili di “off” 
come a determinare il tempo successivo ad 
una dose di farmaco? 
0. No. 
1. Sì. 
 
I periodi di “off” insorgono rapidamente? ( 
per esempio in pochi secondi) 
0. No. 
1. Sì. 
 
In quale percentuale il paziente presenta uno 
stato di "off"nello stato di veglia? 
0. Nessuna. 
1. 1-25% della giornata. 
2. 26-50% della giornata. 
3. 51-75% della giornata. 
4. 76-100% della giornata. 
 
C ALTRE COMPLICANZE 
Il paziente presenta anoressia, nausea o 
vomito? 
0. No 
1. Sì. 
 
Il paziente presenta qualche disturbo del 
sonno? ( per esempio, insonnia o ipersonnia) 
0. No. 
1. Sì. 
 
Il paziente presenta ortostatismo 
sintomatico? 
0. No. 
1. Sì. 
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Allegato 2 HOEHN AND YAHR SCALE 
 
STADIO 0  
Nessun segno di malattia; 
 
STADIO 1  
Coinvolgimento unilaterale; 
 
STADIO 1,5 
Coinvolgimento unilaterale assiale (rigidità del collo); 
 
STADIO 2  
Coinvolgimento bilaterale senza alterazioni dell’equilibrio; 
 
STADIO 2,5  
Coinvolgimento bilaterale con instabilità posturale ma capacità di riprendere l’equilibrio 
quando spinto; 
 
STADIO 3  
Coinvolgimento bilaterale da lieve a moderato, instabilità posturale con incapacità di 
riprendere l’equilibrio se spinto; 
 
STADIO 4  
Disabilità grave, il paziente può ancora camminare o stare in piedi da solo ma è gravemente 
disabile; 
 
STADIO 5 
Il paziente è allettato o in sedie a rotelle se non aiutato. 
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Allegato 3 MMSE 
1) ORIENTAMENTO 
TEMPORO-SPAZIALE 
  
  
 
 MAX PUNTI 5 
Il paziente sa riferire:  
                                                  ANNO 
STAGIONE 
MESE 
GIORNO DEL MESE 
GIORNO DELLA SETTIMANA  
  





  
  
  
  
MAX PUNTI 5 
Il paziente sa riferire:  
                                                   STATO 
REGIONE  
CITTÀ  
LUOGO 
PIANO IN CUI SI TROVA 
  





      
2) MEMORIA DI 
REGISTRAZIONE 
  
 
 
MAX. PUNTI 3 
Il medico pronuncia ad alta voce (una sola volta) il nome di 3 
oggetti (CASA, GATTO, PANE) al ritmo di uno al secondo.  
Il paziente deve ripeterli una prima volta.  
Fa ripetere nuovamente al paziente la sequenza delle 3 
parole fino a quando non le abbia imparate.  


  
 
 
      
3) ATTENZIONE 
CALCOLO 
  
MAX. PUNTI 5  
Sottrazione seriale di 7 da 100 (93-86-79-72-65)  
Fermarsi dopo le prime cinque risposte.  
Se il paziente avesse difficoltà di calcolo, far scandire lettera 
per lettera la parola “MONDO” all’indietro (ODNOM).  

  
  
  
   
4) MEMORIA DI 
RIEVOCAZIONE  
 MAX.PUNTI 3  
Richiamare i 3 termini precedentemente imparati.    
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5) LINGUAGGIO  Il paziente deve riconoscere un oggetto.    
 “Come si chiama questa?” (indicando una MATITA)        
 “Come si chiama questo?”(indicando un OROLOGIO)                  


   
Ripeta “SOPRA LA PANCA LA CAPRA CAMPA”  
1 P.TO  
 
  
  Esecuzione di un COMPITO su comando:    
   a) Con la mano destra prenda questo foglio  
1 P.TO  
  
   b) lo pieghi a metà  
1 P.TO  
  
   c) lo appoggi sulle sue ginocchia  
1 P.TO  
  
  Presentare al paziente un foglio con la seguente scritta 
“CHIUDA GLI OCCHI”. Il paziente deve obbedire all’ordine 

 
 
MAX PUNTI 8 Fare scrivere al paziente una FRASE formata almeno da 
soggetto e verbo   
1 P.TO 


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6) PRASSI 
VISUOCOSTRUTTIVA 
 
 
 
 
MAX 1 PUNTO 
Far copiare al paziente il DISEGNO  
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Allegato 4 FAB 
1. Somiglianza (concettualizzazione) 
- In che cosa sono simili:  
-una banana e un’arancia 
(In caso di fallimento totale: “non sono simili” o di fallimento parziale: “entrambe hanno la 
buccia”, aiutare il paziente : “ la banana e l’arancia sono entrambe ….”; ma assegnare 0 a 
questa risposta; non aiutare i paziente per i due successivi item) 
- un tavolo e una sedia? 
- Un tulipano, una rosa e una margherita?” 
- punteggio: solo le risposte categoriali (frutta, mobili, fiori) sono considerate corrette. 
3 risposte corrette 3 
2 risposte corrette 2 
1 risposta corretta 1 
nessuna risposta corretta 0 
 
2. Fluenza fonemica (flessibilità mentale) 
- “Dica il maggior numero possibile di parole che cominciano con la lettera “S”, qualsiasi parola 
eccetto cognomi o nomi propri”. 
Se il paziente non dà nessuna risposta nei primi 5 secondi, dire: “Per esempio, serpente”. Se il 
paziente si ferma per oltre 10 secondi, stimolarlo dicendo : “Qualsiasi parola che cominci con 
la lettera “S” . La prova dura 60 secondi. 
- Punteggio: ripetizioni o variazioni (scarpa, scarpone), cognomi o nomi propri non sono 
contate come risposte corrette. 
Più di 9 parole 3 
Da 6 a 9 parole 2 
Da 3 a 5 parole 1 
Meno di 3 parole 0 
 
3. Serie Motorie (programmazione) 
- “Guardi con attenzione quello che faccio”. 
L’esaminatore seduto di fronte al paziente effettua tre volte, da solo, con la mano sinistra la 
serie di Luria “pugno-taglio-piatto”. 
- “Ora faccia lo stesso, con la mano destra prima con me poi da solo”. 
L’esaminatore effettua tre volte la stessa serie con il paziente, poi gli dice : “continui da solo” 
- Punteggio: 
- il paziente effettua da solo, correttamente, 6 serie consecutive 3 
- il paziente effettua da solo, correttamente, almeno 3 serie consecutive 2 
- il paziente sbaglia da solo, ma effettua correttamente almeno 3 serie 1 consecutive con 
l’esaminatore 
- il paziente non riesce ad effettuare 3 serie consecutive neppure 0 con l’esaminatore. 
 
4. Istruzioni contrastanti (sensibilità all’interferenza) 
- “Batta due volte quando io batto una volta”. 
Per essere sicuri che il paziente abbia capito le istruzioni, si effettua una serie di tre prove : 
1-1-1. 
- “Batta una volta quando io batto due volte”.Per essere sicuri che il paziente abbia capito le 
istruzioni, si effettua una serie di tre prove :2-2-2. 
L’esaminatore effettua la serie seguente : 1-1-2-1-2-2-2-1-1-2. 
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- punteggio: 
- nessun errore 3 
- 1 o 2 errori 2 
- più di 2 errori 1 
- il paziente batte come l’esaminatore per almeno 0 
4 prove consecutive 
 
5. Go – No - Go (controllo inibitorio) 
- “Batta una volta quando io batto una volta”. Per essere sicuri che il paziente abbia capito le 
istruzioni, si effettua una serie di tre prove : 1-1-1. 
- “Non batta quando io batto due volte”. Per essere sicuri che il paziente abbia capito le 
istruzioni, si effettua una serie di tre prove : 2-2-2-2. 
L’esaminatore effettua la serie seguente : 1-1-2-1-2-2-2-1-1-2. 
- punteggio: 
- nessun errore 3 
- 1 o 2 errori 2 
- più di 2 errori 1 
- il paziente batte come l’esaminatore per almeno 0 
4 prove consecutive 
 
6. Comportamento di prensione (autonomia ambientale) 
- L’esaminatore è seduto di fronte al paziente. Mettere le mani del paziente con le palme in 
alto, appoggiate sulle ginocchia. Senza dire nulla e senza guardare il paziente, l’esaminaotre 
porte le sue mani vicino a quelle del paziente e ne tocca le palme, contemporaneamente da 
ambo i lati, osservando se il paziente spontanemaente le afferra. Se il paziente le afferra, 
l’esaminatore prova di nuovo dopo avergli detto: “Non prenda le mie mani” 
- punteggio : 
- il paziente non afferra le mani dell’esaminatore 3 
- il paziente e vita o chiede cosa deve fare 2 
- il paziente afferra le mani senza esitazione 1 
- il paziente afferra le mani dell’esaminatore 0 
anche dopo che gli ha chiesto di non farlo 
TOTALE …../18 
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Geriatric Depression Scale               SI NO 
1 Siete sostanzialmente soddisfatti della vostra vita?               0 1 
2 Avete abbandonato molte delle vostre attività e interessi?           1 0 
3 La vita vi sembra vuota?                           1 0 
4 Siete spesso annoiati?                            1 0 
5 Avete speranza nel futuro?                          0 1 
6 Siete infastiditi da pensieri che non riuscite a togliervi dalla testa?                           1 0 
7 Siete di buon umore per la maggior parte del tempo?              0 1 
8 Avete paura che qualcosa di brutto stia per accadervi?             1 0 
9 Vi sentite felice per la maggior parte del tempo?                0 1 
10 Vi sentite spesso senza speranza?                      1 0 
11 Vi sentite spesso irrequieto e agitato?                    1 0 
12 Preferite rimanere in casa piuttosto che uscire e fare cose nuove?                               1 0 
13 Il futuro vi preoccupa?                        1 0 
14 Vi sembra di avere dei problemi di memoria più degli altri?           1 0 
15 Vivere, per voi, è meraviglioso?                        0 1 
16 Vi sentite spesso giù di corda e malinconico?                  1 0 
17 Vi sentite inutile nella vostra situazione?                   1 0 
18 Vi tormentate molto pensando al passato?                  1 0 
19 Trovate la vita molto interessante?                      0 1 
20 È difficile per voi iniziare delle nuove cose?                  1 0 
21 Vi sentite carichi di energie?                         0 1 
22 Vi sembra che la vostra situazione sia senza speranza?             1 0 
23 Pensate che la maggior parte delle persone stia meglio di voi?                           1 0 
24 Siete spesso agitati per cose poco importanti?                 1 0 
25 Avete frequentemente voglia di piangere?                  1 0 
26 Avete difficoltà a concentrarvi?                       1 0 
27 È un piacere per voi alzarvi al mattino?                    0 1 
28 Preferite evitare di incontrare gente?                     1 0 
29 Vi riesce facile prendere delle decisioni?                   0 1 
30 Vi sembra che la vostra mente sia lucida come prima?             1 0 
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 QUESTIONARIO SULLA QUALITÀ DELLA VITA DEI MALATI DI PARKINSON 
 
COGNOME E NOME ________________________________  ANNI ______ 
DATA DI NASCITA ________ 
 
A causa del morbo di parkinson, quanto spesso si è trovato/a nelle seguenti situazioni, nel 
mese scorso? 
La preghiamo di segnare una sola casella per ogni domanda. 
 
1. Ha avuto difficoltà nello svolgere attività di tempo libero come avrebbe voluto? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
2. Ha avuto difficoltà nello svolgere attività domestiche, p.e. bricolage, faccende 
domestiche, cucinare? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
3. Ha avuto difficoltà nel portare le borse della spesa? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
4. Ha avuto problemi nel camminare per circa un chilometro? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
5. Ha avuto problemi nel camminare per circa 100 metri? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
6. Ha avuto problemi nel muoversi per casa senza difficoltà come avrebbe voluto? 
MAI 
OCCASIONALMENTE 
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QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
7. Ha avuto difficoltà nel muoversi in luoghi pubblici? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
8. Ha avuto bisogno dell’aiuto di qualcuno per uscire di casa? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
9. Ha avuto paura o si è preoccupato/a di poter cadere quando si è trovato/a in 
pubblico? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
10. È stato/a costretto/a a restare in casa più di quanto avesse desiderato? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
11. Ha avuto difficoltà nel lavarsi? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
12. Ha avuto difficoltà nel vestirsi? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
13. Ha avuto problemi nell’abbottonare i vestiti o allacciarsi le scarpe? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
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14. Ha avuto problemi nello scrivere in modo chiaro? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
15. Ha avuto difficoltà nel tagliare il cibo? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
16. Ha avuto difficoltà nel tenere in mano il bicchiere senza versarne il contenuto? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
17. Si è sentito/a depresso/a? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
18. Si è sentito/a isolato/a e abbandonato/a? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
19. Ha avuto voglia di piangere o è stato/a sul punto di farlo? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
20. Si è sentito/a pieno/a di rabbia o risentimento? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
21. Si è sentito/a ansioso/a? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
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SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
22. Si è sentito/a preoccupato/a per il suo futuro? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
23. Ha voluto cercare di nascondere agli altri la propria malattia? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
24. Ha cercato di evitare occasioni che le richiedevano di mangiare o bere in pubblico? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
25. Ha provato imbarazzo in pubblico a causa del morbo di Parkinson? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
26. Si è sentito/a preoccupato/a a causa della reazione degli altri nei suoi confronti? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
27. Ha avuto problemi nelle relazioni personali con le persone che le sono vicine (amici 
intimi, parenti stretti)? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
28. Le è mancato il sostegno da parte del coniuge o compagno/a? 
Se non ha coniuge o campagno/a la preghiamo di fare un segno in questa casella 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
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29. Le è mancato il sostegno da parte di familiari o amici intimi? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
30. Si è addormentato/a improvvisamente durante il giorno? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
31. Ha avuto problemi di concentrazione, p.es. leggendo o guardando la TV? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
32. Ha avuto l’impressione di avere problemi di memoria? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
33. Ha fatto sogni angosciosi o ha avuto allucinazioni? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
34. Ha avuto difficoltà nel parlare ed esprimersi? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
35. Si è sentito/a incapace di comunicare correttamente con gli altri? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
36. Si è sentito/a ignorato/a dagli altri? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
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SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
37. Ha avuto crampi o spasmi muscolari dolorosi? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
38. Ha avuto dolori alle articolazioni o ad altre parti del corpo? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
 
39. Ha provato una spiacevole sensazione di caldo o freddo? 
MAI 
OCCASIONALMENTE 
QUALCHE VOLTA 
SPESSO 
SEMPRE O NON CI RIESCE AFFATTO 
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Allegato 7 TMT-A 
 
Trail Making Test Part A 
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